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SUMMARY 
 
Senile degenerative calcific aortic valve stenosis (AVS) is a progressive disease 
characterized by a peculiar natural history. When symptoms begin (congestive heart 
failure and dyspnea, angina, syncope) mortality rate rapidly increase and quality of life 
dramatically worsen. It has been estimated that the overall survival of patients with 
severe symptomatic AVS is less than 50% 2 years after the onset of symptoms. The 
number of patients suffering from AVS worldwide will increase over time as life 
expectancy progressively extends. 
The treatment of choice for severe symptomatic AVS is aortic valve replacement (AVR) 
that is usually performed under general anesthesia, with median sternotomy and 
cardiopulmonary bypass. AVR is a well-established procedure, with excellent early and 
long-term results and valve prostheses have now reached optimal hemodynamic 
performance and duration. During the last few years, the development of sutureless 
aortic bioprosthesis has made easier the surgical procedure. In fact, aortic valve 
replacement with sutureless valves (SU-AVR) needs shorter cardiopulmonary bypass 
and aortic cross clamp times and can be safely performed through a minimally invasive 
approach.  
However, a recent survey showed that around 30% of patients with severe symptomatic 
AVS does not undergo AVR for several reasons: they are not referred for surgery by 
their family physician or by their cardiologist because of age, they are declined surgery 
for a high preoperative risk profile; they are inoperable for severe ascending aortic 
calcification (porcelain aorta).  
Trans-catheter aortic valve implantation (TAVI) is an alternative therapeutic option in 
high-risk or inoperable patients. TAVI can be performed through several accesses: 
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trans-femoral (TF-TAVI), trans-apical (TA-TAVI), trans-aortic (TAo-TAVI) and trans-
subclavian (TS-TAVI). This thesis will focus on TAVI and in particular on TA-TAVI in 
terms of, indications, technique and outcomes. 
We will show the results of the Italian Registry of Trans-Apical Aortic Valve Implantation 
(I-TA) that includes the great majority of patients who underwent TA-TAVI in Italy since 
this procedure became commercially available in 2008. Furthermore we will present the 
results of a propensity-matched study that compared all the three available surgical 
options for patients with severe symptomatic aortic valve stenosis: surgical aortic valve 
replacement (SAVR), SU-AVR and TA-TAVI. From the results of these two studies it 
clearly appears that TA-TAVI is an excellent therapeutic options in patients with aortic 
valve stenosis. The two main issues that still need to be solved are the incidence of 
paravalvular leak, and valve durability. Paravalvular leak has been demonstrated to 
have a significant impact on long term survival while the assessment of valve durability 
needs a longer observation of these patients in order to reach time points when 
structural valve deterioration is more likely to occur. 
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RIASSUNTO 
 
La stenosi valvolare aortica (AVS) degenerativa senile è una malattia ad evoluzione 
progressiva caratterizzata da un significativo aumento della mortalità e da un 
drammatico peggioramento della qualità della vita dal momento in cui compare la 
sintomatologia specifica: dispnea (scompenso cardiaco congestizio), angina e sincopi. 
É stato dimostrato che, dalla comparsa dei sintomi, la sopravvivenza a due anni è 
inferiore al 50%. La diffusione di questa patologia è in aumento in seguito al 
progressivo incremento dell’aspettativa di vita, specialmente nei paesi più sviluppati. Il 
trattamento di prima scelta nei pazienti affetti da AVS severa sintomatica è 
rappresentato dall’intervento chirurgico di sostituzione valvolare. Questa procedura è 
generalmente eseguita in anestesia generale attraverso una sternotomia longitudinale 
mediana e con l’utilizzo della circolazione extracorporea. I risultati dell’intervento di 
sostituzione valvolare aortica sono ormai ben conosciuti, la sopravvivenza a breve e 
medio termine è eccellente e le protesi utilizzate hanno dimostrato delle ottime 
performance sia in termini di durata sia dal punto di vista emodinamico. Negli ultimi 
anni sono state introdotte sul mercato le bioprotesi aortiche sutureless che non 
richiedono punti di sutura per ancorarsi sull’anulus aortico. L’intervento di sostituzione 
valvolare aortica con le protesi sutureless (SU-AVR) richiede, infatti, dei tempi di 
clampaggio aortico e di circolazione extracorporea inferiori rispetto alle protesi 
tradizionali ed inoltre può essere più agevolmente eseguito attraverso un accesso mini-
invasivo.  
Ciononostante, una recente analisi ha evidenziato che circa il 30% dei pazienti affetti 
da stenosi aortica non sono sottoposti all’intervento cardiochirurgico a causa dell’età 
molto avanzata o delle severe patologie associate da cui sono affetti.  
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L’impianto valvolare aortico trans-catetere è un’alternativa terapeutica che può essere 
considerata nei pazienti ritenuti inoperabili con la tecnica tradizionale  oppure per 
coloro che vengono considerati ad altissimo rischio a causa delle severe patologie 
coesistenti.  
La procedura di TAVI può essere eseguita attraverso diversi approcci: trans-femorale 
(TF-TAVI), trans-apicale (TA-TAVI), trans-aortico (Tao-TAVI) e trans-succlavio (TS-TAVI). 
L’argomento di questa Tesi sarà la procedura di TAVI e in particolare rivolgeremo la 
nostra attenzione alla TAVI trans-apicale in termini d’indicazioni, tecniche e risultati. 
In questa tesi saranno presentati i risultati del Registro italiano dell’Impianto Valvolare 
Aortico per via Trans-Apicale (I-TA registry), in cui sono stati arruolati la grande 
maggioranza dei pazienti sottoposti a TA-TAVI in Italia dal 2008, anno in cui questa 
tecnica è stata disponibile. Verranno inoltre presentati i risultati di uno studio 
propensity-matched in cui sono stati confrontati i risultati di tutte le tre tecniche 
chirurgiche attualmente disponibili per il trattamento dei pazienti con AVS: SAVR, TA-
TAVI e SU-AVR. Dai risultati di questi studi appare chiaramente che la TA-TAVI è una 
valida alternativa terapeutica nei pazienti con AVS. Ci sono tuttavia ancora due aspetti 
che richiedono particolare attenzione: l’incidenza di leak paravalvolari e la durata di 
queste nuove bioprotesi. La presenza di un leak paravalvolare si è dimostrata un fattore 
prognostico negativo in termini di sopravvivenza a distanza mentre un’effettiva 
valutazione della durata di queste protesi richiede un’osservazione più prolungata in 
modo tale da arrivare ad intervalli di tempo in cui il verificarsi di una degenerazione 
strutturale sia più probabile. 
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1. THE AORTIC VALVE 
 
1.1 Anatomy of the aortic valve and of the aortic root 
The first accurate description of the aortic valve was made by Leonardo Da Vinci 
between 1508 and 1513. Leonardo, in the “Corpus of Anatomical Studies” 
(Collection of Her Majesty the Queen at Windsor Castle) describes, through 
several drawings, anatomy, geometry, dynamics and physiology of the aortic 
valve and its leaflets. He was the very first scientist to understand the 
importance of curly vortices in Valsalva sinuses and the mechanisms of leaflets 
coaptation (Fig.1-2). 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
Fig.1:  Schematic drawing of the aort ic valve made by 
Leonardo Da Vinci . From the "Corpus of anatomical  
studies" in the Collect ion of Her Majesty  the Queen at 
Windsor cast le 
________________________________________________________________ 
Fig.2:  Curly  vort ices in the aortic  root by Leonardo Da Vinci. 
From the "Corpus of anatomical studies" in the Collection of 
Her Majesty the Queen at Windsor cast le 
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The aortic root provides the supporting structures for the leaflets of the aortic 
valve, and forms the bridge between the ascending aorta and the left ventricle. 
The aortic root, which surrounds and supports the leaflets, extends from the 
leaflet attachments until the sino-tubular junction. The anatomic ventricular-
aortic junction is a circular locus within the root, placed where the supporting 
ventricular structures give way to the fibro-elastic walls of the aortic sinuses. This 
ring is markedly discordant with the morphology of the attachment of the 
leaflets of the aortic valve.  
 
1.1.1 The “aortic annulus”  
In order to fully understand the anatomical basis of aortic valve surgery and in 
particular of trans-catheter aortic valve implantation, it is important to describe 
the complex structure of the aortic annulus. Under a surgical point of view, the 
aortic annulus is generally considered as the structure where aortic leaflets are 
attached to the aortic wall. This 
structure has a crown-like 
morphology. For TAVI, the annulus 
is better described by the concept 
of the “virtual basal ring”(1) 
constructed by joining together 
the most proximal parts (“nadir”) of each leaflet (Fig. 3). 
_______________________________________________________________________________________________ 
Fig.  3:  The “crown-like” shape of the surgical 
aort ic annulus (red, blue and yellow lines) and the 
“virtual basal  r ing” (green l ine) 
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The latter definition, the so-called “virtual basal ring” is typically analyzed by 
the echocardiographer and the radiologist when providing measurements and 
relationships of the annulus diameter and is carefully considered by the 
implanting physician when planning and performing a TAVI procedure. In fact, 
valve sizing is a crucial step of procedural planning for TAVI. In order to achieve 
optimal results, a good evaluation of patient’s aortic valve and annulus in terms 
of morphology (bicuspid, tricuspid), shape (circular, oval), dimensions 
(diameters, perimeter, area) and distance from the coronary ostia is of outmost 
importance. It is also important to measure the diameter of the sino-tubular 
junction and to assess the shape of Valsalva sinuses as well as the aspect of the 
left ventricular outflow tract. In other words, an in-depth analysis of the entire 
complex left ventricle outflow tract (LVOT)-aortic root anatomy is mandatory to 
carry out a successful TAVI procedure.  
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2. AORTIC VALVE STENOSIS 
 
Aortic valve stenosis (AVS) is an insidious disease that has a slow but inexorably 
progressive evolution. It is a consequence of reduction of aortic valve area that 
creates an obstruction to blood flow that ultimately generates a trans-valvular 
pressure gradient with consequent left ventricular hypertrophy. When 
symptoms appear, the disease rapidly progresses towards death if it is left 
untreated (2,3). The incidence of AVS increases with age; after 65 years around 
2% of the general population is affected and 29% has echocardiographic signs 
of leaflet calcifications (4).  
 
2.1 Etiology 
The causes of aortic valve stenosis can be categorized as congenital and 
acquired.  
There are three types of 
congenital aortic valve 
stenosis: supra-valvular, sub-
valvular and valvular. The 
latter is generally due to 
unicuspid, bicuspid or 
malformed tricuspid valves. 
AVS was found in 85% of 
__________________________________________________________ 
Fig.  4:  Senile calcific  degenerat ive aortic valve stenosis 
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patients with bicuspid aortic valve but only 33% shows severe clinical 
consequences (5). 
Acquired causes of AVS are mainly two: rheumatic disease and senile calcific 
degeneration. The post-inflammatory rheumatic disease of the aortic valve is 
characterized by commissural fusion and leaflet retraction and is caused by an 
immune-mediated reaction that is generated by a Group A Beta hemolytic 
Streptococci infection of the upper airways. Clinical symptoms of AVS in these 
cases generally occur in the sixth decade of life.  
Senile degeneration is the most frequent cause of AVS and generally occurs in 
the seventh or eighth decade of life, maybe due to the progressive increase of 
life expectancy, especially in western countries.  It has been recently 
demonstrated that this degeneration is an active proliferative and at the same 
time inflammatory process that causes lipid accumulation, up-regulation of 
Angiotensin Converting Enzyme and also infiltration of macrophages and T-
lymphocytes. All together these processes ultimately lead to valve calcification 
(6). Usually the first lesions appear on the aortic side of the leaflets and with 
time they proceed deep in the annulus and in the interventricular septum. 
These lesions are mainly made of localized deposits of calcium together with 
inflammatory cells and cholesterol infiltration (Fig. 4). 
 
Cholesterol has been identified as an important initiator of the degenerative 
process that affects valve leaflets creating a progressive atherosclerotic process 
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through the activation of transcriptional regulators such as Osteopontin and 
Cbfa1 that are involved in osteoblasts differentiation.  
Furthermore, other well known risk factors for the development of 
atherosclerosis such as high blood levels of LDL, Apolipoprotein A, diabetes 
mellitus, smoke, arterial hypertension and male sex have been identified as 
predictors of aortic valve stenosis (7,8) 
 
2.2 Pathophysiology  
Normal aortic valve area is 3-4 cm2. Table 1 shows the classification of aortic 
valve stenosis according to recent American College of Cardiology/American 
Heart Association guidelines (9).  
 
 
 Mild Moderate Severe 
Jet velocity (m/s) <3.0 3.0-4.0 >4 
Mean Gradient (mmHg) <25 25-40 >40 
Valve area index (cm2/m2)   <0.6 
Valve area >1,5 1.0-1.5 <1.0 
 
Reduction of aortic valve area represents an obstacle to cardiac outflow. As a 
consequence, the left ventricle reacts with a compensatory hypertrophy due to 
an over expression of genes encoding for collagen type I and II and for 
Table 1.  Classi fication of aortic  valve stenosis severity 
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fibronectin (10) in order to maintain an adequate cardiac output and to reduce 
wall stress. The result of these compensatory mechanisms is that aortic valve 
stenosis may be completely asymptomatic for many years. As the ventricle 
becomes hypertrophic, it becomes stiffer as its compliance decreases; a higher 
left ventricular end-diastolic pressure is needed to maintain the same volume of 
cardiac output. To achieve a sufficiently high left ventricular end-diastolic 
pressure (diastolic loading), the heart becomes increasingly dependent on the 
atrial kick; loss of the atrial kick, as occurs with atrial fibrillation, may result in a 
significant decline in cardiac output and acute hemodynamic impairment. The 
combined effects of bigger mass of the left ventricle due to compensatory 
hypertrophy; less compliance of the left ventricle (LV) that consequently leads to 
more wall tension and higher systolic ventricular pressure ultimately generate an 
increase in myocardial oxygen demand. At the same time, coronary artery 
blood flow is compromised by increased wall tension compressing the vessels 
and by higher left ventricular diastolic pressure, which lowers the coronary 
artery perfusion pressure. These factors contribute to inadequate coronary 
arterial perfusion of the sub-endocardium, leading to chronic ischemia with cell 
necrosis and fibrosis. Left ventricular hypertrophy may allow the heart to achieve 
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a normal cardiac output under resting conditions. To do so, however, a pressure 
gradient across the valve is required, and, as the aortic valve area (AVA) 
becomes smaller, the gradient across the valve from left ventricle to aorta 
increases. The relationship of flow across the aortic valve and the trans-valvular 
pressure gradient is shown in Figure 5. 
As the valve area decreases to 1 cm2, there is little change in the trans-valvular 
gradient needed to generate the same flow, and patients frequently experience 
no symptoms. With a valve area of 0.8 cm2, patients invariably develop 
symptoms. 
 
2.3 Natural History and Symptoms 
The natural history of aortic stenosis was reported by Ross and Braunwald 
(2). Patient survival is not reduced until symptoms occur and this generally 
happens when aortic valve area reduces from the normal 3-4 cm2 to less than 1 
cm2. After symptoms occur, patient 
survival is drastically reduced. The 
three principal symptoms of aortic 
stenosis are angina, syncope, and 
dyspnea (or congestive heart 
failure) (Fig. 6). 
 
___________________________________________________________________________________________ 
Fig 5:  Relationship between flow across the 
aort ic valve and the trans-aort ic gradient 	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Angina is usually the 
earliest symptom, and 
the mean survival of a 
patient with aortic 
stenosis and angina is 
4.7 years. Angina is 
present in around 50-70% 
of patients with severe aortic valve stenosis. Reduced myocardial perfusion is 
due to ventricular hypertrophy and to an increased end-diastolic pressure and is 
particularly evident in the sub-endocardium muscular layer. When patient 
experiences syncope, survival is typically less than 3 years. Syncope is due to 
the reduced blood flow through the stenotic valve that causes a decreased 
cerebral perfusion; furthermore, peripheral vasodilatation that occurs during 
exercise may worsen the situation since cardiac output does not modify. 
Patients with dyspnea and congestive heart failure, in keeping with their 
associated left ventricular dysfunction, have a mean survival of 1 to 2 years. 
Congestive heart failure is the presenting symptom in nearly one third of 
patients. Dyspnea is the consequence of the reduced capacity of the heart to 
increase the stroke volume in response to an increased metabolic demand. It 
can be also a consequence of the diastolic dysfunction (11). 	  	  
_________________________________________________________________________________________________________ 
Fig 6 Natural history of  aortic valve stenos is 
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2.4 Treatment 
Although conventional aortic valve replacement is the treatment of choice for 
patients with severe symptomatic aortic valve stenosis and can be generally 
considered as a routine operation, the progressive increase in life expectancy is 
leading to a parallel increase in the mean age of patients referring to the 
surgeon for severe aortic valve stenosis. For this reason, the need for newer and 
less invasive options, such as sutureless valves and trans-catheter techniques, 
has emerged during the last decade.  
There are four therapeutic options for the treatment of patients suffering from 
severe symptomatic aortic valve stenosis: 
 
1. Balloon aortic valvuloplasty (BAV) 
2. Conventional surgical aortic valve replacement (SAVR) 
3. Trans-catheter aortic valve implantation (TAVI) 
4. Sutureless aortic valve replacement (SU-AVR) 
 
The choice between these four different techniques is based on age, surgical 
risk profile, anatomical characteristics and physician’s preferences. The following 
chapters will focus on each treatment option highlighting indications, results 
and devices. 
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3. BALLOON AORTIC VALVULOPLASTY 
 
Balloon aortic valvuloplasty plays an important role in the pediatric population 
but a very limited role, when used in isolation, in adults: this is because its 
efficacy is low, the complication rate is high (>10%), and restenosis and clinical 
deterioration occur within 6–12 months in most patients, resulting in a mid- and 
long-term outcome similar to natural history (12), as shown in figure 7. 
 	  
 
 
 
 
 
 
 
BAV is generally performed through femoral access and a retrograde approach 
to the aortic valve. Balloon inflation is usually performed under rapid ventricular 
pacing (160–220 beats/min). Rapid ventricular pacing helps to temporarily 
reduce myocardial contractility in order to establish a stable balloon position 
 
____ _______ ____ _______ _______ _______ _______ ______ _______ _______ _______ _______ _______ _______ _______ _______ _______ ______ _______ _______ ________ ______ 
Fig 7 Kaplan-Meier curves showing that there is no di fference between balloon aort ic 
valvulop lasty alone (PABV, green l ine) and medical treatment (red l ine) in terms of long 
term prognos is in pat ients with severe aortic valve stenosis.  PABV: Percutaneous aortic  
balloon valvuloplasty;  TAVI:  Trans-catheter aortic  valve replacement;  AVR: Aortic  valve 
replacement.  
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during inflation. According to the most recent guidelines issued by the 
European Society of cardiology in 2012, BAV may be considered as a bridge to 
surgery or TAVI in selected high-risk patients or in patients with symptomatic 
severe aortic stenosis who require urgent major non-cardiac surgery 
(Recommendation class IIb, level of evidence C) (13).  
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4. CONVENTIONAL AORTIC VALVE REPLACEMENT 
 
Conventional surgical aortic valve replacement (SAVR) is the gold standard as 
well as the benchmark procedure for severe AS. SAVR is a routine procedure 
that has been performed in many centers throughout the world for more than 
50 years. Results are generally excellent, depending on the individual patient 
risk profile together with the experience of the surgeon. Operative mortality of 
isolated AVR for AS ranges from 0.5–3% in patients younger than 70 years and 
4–8% in selected older adults. Older age, associated comorbidities, female 
gender, higher functional class, emergency operation, LV dysfunction, 
pulmonary hypertension, co-existing coronary artery disease (CAD), and 
previous bypass or valve surgery were identified as independent predictors for 
hospital mortality following AVR (14-21). Standard access for AVR is through a 
full median sternotomy. Alternatively, minimally invasive access, using a partial 
mini-sternotomy, can be done with good outcomes; this will be discussed in the 
next paragraph. Conventional AVR requires cardiopulmonary bypass and aortic 
cross clamping. The diseased aortic valve is excised and the valve prosthesis is 
implanted under direct surgical vision after careful measurement of the aortic 
root thus reducing the risk of leak and optimizing hemodynamic outcomes. The 
2011 report from the German cardiac surgical national database shows good 
outcomes in more than 11000 patients receiving AVR every year, with an 
average mortality of 3% (22). Freedom from valve related mortality in patients 
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with mechanical prostheses is 90% at 10 years (23) while freedom from 
structural valve degeneration was is around 90-95% at 15 years with small 
variations depending on the age at the time of surgery and also on the type of 
implanted prosthesis (porcine, pericardial, stented, stentless) (24). After 
successful AVR, symptoms and quality of life are in general greatly improved 
and in elderly patients long-term survival is similar to that of an age and sex 
matched population (25). Age, comorbidities, severe symptoms, LV dysfunction, 
ventricular arrhythmias and untreated co-existing CAD were identified as 
independent predictors of late death. Valve-related complications and 
suboptimal prosthetic valve hemodynamic performance may cause poor 
postoperative outcome. Generally patients 65 years or younger are considered 
candidates for mechanical valves, whereas patients aged from 65 years upwards 
are considered candidates for xenografts. However, as we will see in the next 
chapters, the possibility to perform a “valve-in-prosthesis” implantation using a 
trans-catheter valve may lead to lower the threshold for using xenografts with 
the option of subsequent valve-in-prosthesis implantation in case of xenograft 
degeneration. 
 
4.1 Minimally invasive SAVR. 
Minimally invasive access modalities are aimed at reducing the length of 
incision in order to minimize the effects of surgical trauma. Generally “J-shape” 
or “inverted T” in the 3rd or 4thintercostal space are performed. Aortic 
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cannulation is generally directly made in the ascending aorta while venous 
cannulation can be performed directly in the right atrium or percutaneously 
through the femoral vein. Overall, results of minimally invasive AVR are 
comparable to a complete sternotomy approach (20). In a meta-analysis of 4586 
patients (2054 mini-sternotomy vs. 2532 full sternotomy) mini-sternotomy was 
proven to be as safe as conventional sternotomy for AVR, without increased risk 
of death or any other major complication (26). Major benefits of this technique 
are related to better and more rapid postoperative recovery and to better 
aesthetic results.  
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5. SUTURELESS AORTIC VALVE REPLACEMENT (SU-AVR). 
 
In the last few years many companies have developed new aortic sutureless 
bioprosthesis. This procedure is similar to conventional SAVR, the only 
difference being that the surgeon does not need to suture the valve to the 
annulus but the valve anchors to the annulus thanks to the radial force of its 
stent. This leads to a more rapid implantation. The advantages of sutureless 
valves include: 
• Complete excision of the diseased valve 
• Anatomical tailoring to individual patient anatomy 
• A-traumatic introduction with minimal or no crimping of the valve leaflets 
allowing more predictable long-term outcomes 
• Valves are self-anchoring (no need for sutures), self-expanding for easy 
implantation and good visibility 
• Shorter aortic cross clamping and cardiopulmonary bypass times 
• Easier minimally invasive cardiac surgery procedures. 
There may be a specific subset of patients that could particularly benefit 
from sutureless devices - for example, those with an increased risk profile 
who require a fast procedure through a small incision.  
Three different prostheses have undergone initial clinical studies and 
received approval for use in the European Community (CE mark): Medtronic 
3F Enable (Medtronic, Minneapolis, Minnesota, USA), Sorin Perceval S (Sorin 
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Group, Saluggia, Italy) and Edwards Intuity (Edwards Lifesciences, Irvine, 
California, USA). 
 
5.1 Medtronic 3F Enable Valve 
It is based on the ATS 3F Aortic Bioprosthesis with an 
added self-expanding nitinol frame to hold the valve in its 
position (Fig. 8).  
It has three equine pericardial leaflets (27, 28). A 
multicenter clinical study evaluated the safety and 
efficacy of this bioprosthesis in 140 patients undergoing 
isolated aortic valve replacement with or without concomitant procedures. 
Mean systolic gradient was 9.04 ± 3.56 and 8.62 ± 3.16 mm Hg with mean 
effective orifice area of 1.69 ± 0.52 and 1.67 ± 0.44 at 6 months and 1 year, 
respectively. Severe paravalvular leaks requiring valve removal were 
observed in 2.1% of patients. No structural deterioration, valve-related 
thrombosis or hemolysis was documented in the total accumulated follow-
up of 121.8 patient-years (29).  
 
5.2 Sorin Perceval S 
Sorin Perceval S (Fig. 9) is made of a nitinol frame and bovine pericardial 
leaflets. Sinusoidal struts anchor the device in the Valsalva sinus and annular 
sealing is obtained with brief low-pressure balloon dilation. 
_____________________________________ 
Fig.  8.  Medtronic 
3F Enable 
Sutureless aort ic 
bioprosthesis  
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A European, multicenter, prospective trial evaluated 
its feasibility in 30 patients. The mean aortic cross-
clamp and extracorporeal cardiac circulation (ECC) 
times were 34±15 min and 59±min, respectively. 
Hospital mortality was 3.3%. No migration or 
dislodgement of the valve occurred, but there were 
two mild paravalvular leakages and two mild intra valvular insufficiencies 
(30). In a follow up study, mean aortic cross-clamp time for aortic valve 
replacement was 18±6 minutes. This was associated with excellent early 
clinical and hemodynamic outcome in high-risk patients (31). 
 
5.3 Edwards Intuity 
This prosthesis is based on the Magna Ease aortic 
valve. It is a stented tri-leaflet bovine pericardial 
bioprosthesis with a balloon expandable, cloth-
covered stent frame at the inflow aspect (Fig. 
10).  
The valve is positioned supra-annularly using three guiding sutures. The sutures 
are tied and the frame is expanded with a balloon catheter. Data from the 
TRITON study (32), a multi-center European prospective study in 152 patients 
___________________________________________________________	  
Fig.  9.  Sor in Perceval  S 
sutureless aort ic 
bioprosthesis 
___________________________________	  
Fig.  10. Edwards Intuity 
sutureless aortic  
bioprosthesis 
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showed a technical success rate of 96.1%. In isolated AVR, mean aortic cross-
clamp times was41.1 ｱ 10.6 (reduced by 43% if compared to data from the STS 
National Database).  All-cause and valve-related early mortality were 2.1% 
(3/146) and 1.4% (2/146), respectively. Two early cases of paravalvular leaks 
(1.4%) (2/146) that remained unchanged over 1 year were reported. 
Furthermore one late moderate/severe paravalvular leak (0.9%), which required 
removal of the study device was reported.
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6. TRANS-CATHETER AORTIC VALVE IMPLANTATION (TAVI). 
 
6.1 History  
A large percentage of suitable candidates for AVR are currently not referred for 
surgery or are turned down by the cardiac surgeon due to advanced age or 
severe comorbidities. 
 
 
 
 
 
The first description of a trans-catheter aortic valve implantation was made by 
Davies who, in 1965, implanted a parachute-like valve in the descending aorta 
of a dog through a trans-femoral access (Fig. 11) (33, 34).  
 
Six years later, in1971, Moulopoulos et al described three different trans-
catheter valve systems, which were temporarily placed in the ascending aorta of 
dogs with aortic regurgitation (Fig. 12) (35)  
_______________________________________________________________________	  
Fig.  11. The first t rans-catheter valve developed 
by Davies  in 1965 
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Since then on, many different 
devices were tested in animals. 
All these valves were designed 
for palliation of aortic 
regurgitation and were generally 
considered as temporary. In the 
eighties, Alain Cribier developed 
balloon aortic valvuloplasty in 
patients suffering from aortic stenosis. (36). This technique showed promising 
initial results but longer follow-up demonstrated that there was a high incidence 
of recurrence of aortic stenosis and also that survival was similar to that of 
untreated patients (37). By 1992, Andersen had reported the permanent sub-
coronary implantation of a trans-catheter aortic valve in pigs (38). The valve was 
constructed of surgical stainless-
steel wires folded in repeated loops. 
A porcine aortic valve was sewn 
inside the stent, and the valve was 
crimped on a balloon catheter    
(Fig. 13).  
Andersen used a retrograde trans-
aortic approach to implant this 
________________________________________________ 
Fig.  12. Umbrella and balloon trans-catheter 
valves descr ibed by Moulopous in 1971. 
These dev ices were connected to an external 
pump that caused inf lat ion dur ing diastole 
and deflat ion dur ing systole in order to 
reduce aortic  regurgitat ion . 
_______________________________________________________________	  
Fig.  13.  Trans-catheter aortic  valve 
developed by Andersen in 1992.  
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hand-made device in nine pigs. Hemodynamic results were excellent: low 
gradients and trivial paravalvular regurgitation. However, coronary flow 
reduction was observed in one-third of cases.  
Although the TAVI procedure of today (with balloon-expandable valves) follows 
the concept first pioneered by Andersen, it took a further decade to refine and 
ultimately translated the principle of this technique into clinical practice. In 
2002, Cribier performed the first-in-human TAVI procedure using an antegrade, 
trans-venous approach (Fig. 14-15) (39). 
A	  
B	  
_______________________________________________________________________________________________ 
Fig. 14. The first trans-catheter valve, open (A) and crimped on the balloon catheter (B) 
developed by Alain Cribier and implanted for the f irst t ime in a human being in 2002. 
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_______________________________________________________________________________________________ 
Fig. 15. Fluoroscopic images of the f irst human implantation of the trans-catheter valve 
developed by Cribier. In this case a trans-femoral venous approach with a trans-septal 
puncture was used. PHV: Percutaneous heart valve; RCA: Right coronary artery; LCA: Left 
coronary artery. 
The valve was made of equine pericardium sewn inside a balloon-expandable 
metal stent. However, the technical complexity and associated risks of the trans-
venous approach limited its widespread application and rapidly it was 
abandoned in favor of the retrograde trans-femoral procedure. This allowed a 
more technically feasible and reliable procedure. During the same period, the 
first-in-human TAVI with a self-expandable valve was reported by Grube (40). 
Shortly after this, the first-in-human trans-apical procedures were performed 
through a median sternotomy and with the use of cardiopulmonary bypass in 
Leipzig and through left thoracotomy without extracorporeal circulation in 
Vancouver, providing an alternative option for patients without suitable vascular 
access (41-43). 
At the beginning, TAVI was an investigational procedure restricted to 
inoperable patients with symptomatic severe native valve AVS. Subsequently, 
and despite a steep learning curve, the initial success documented in small 
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observational registries (44-46) from a limited number of pioneering centers 
paved the way for large randomized trials to be performed. On the basis of 
registry data, European CE mark approval for trans-femoral implantation was 
received for the Medtronic CoreValve in 2007, followed by the Edwards SAPIEN 
in 2008. 
In the United States, the Food and Drug Administration restricts approval to 
new devices only after large prospective randomized trials. The Placement of 
AoRTic Trans-catheter Valves (PARTNER) Trials were the first prospective 
randomized multicenter landmark studies, which compared TAVI with medical 
management (and optional BAV) in inoperable patients (PARTNER Trial Cohort 
B) (47, 48) and with surgical AVR in patients considered to be at high operable 
risk (PARTNER Trial Cohort A) (49). Compared with standard medical 
management there was an absolute reduction in mortality of 20% with TAVI at 1 
year and even greater benefit after 2 years. The FDA approved the Edwards 
SAPIEN device for trans-femoral delivery in 2011 and for trans-apical access in 
2012. Similarly, approval of CoreValve by the FDA is dependent on the results 
of the ongoing Medtronic CoreValve US Pivotal Trial that will enroll around 
1600 patients and has an estimated study completion date of November 2017. 
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6.2 The “TAVI team” 
In order to carry out a successful TAVI program a strong synergy between 
different specialists is mandatory. The “TAVI TEAM” includes a cardiologist, a 
cardiac surgeon, an interventional cardiologist, an echocardiographist, an 
anesthetist and a radiologist. In order to guarantee an optimal safety profile to 
these extremely delicate patients, all these specialists should be part of a high-
level health facility. Components of the TAVI team should participate in all the 
steps of a potential TAVI candidate: patient selection and screening, 
preoperative diagnostic pathway, access choice, TAVI procedure and managing 
of complications. In particular, the construction of a reliable surgical “safety 
net”, with immediate access to extracorporeal circulation and surgical 
conversion guarantees the best treatment of complication that might occur 
during TAVI (50). 
 
6.3 The Procedure 
The procedure is best performed by the components of the “Heart Team”. 
Depending on the logistics of each center, the procedure may be performed in 
a standard catheterization laboratory, an operating room, or a hybrid room. The 
hybrid room is the ideal setting for a TAVI procedure since it combines the 
advantages of an operating room, providing adequate sterility and a laminar air 
flow system as well as immediate availability to the cardiopulmonary bypass 
machine, with the advantages of a catheterization laboratory with high-
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resolution images. Moreover, combining the needs of cardiovascular surgeons 
and interventional cardiologists in one dedicated room allows for an easy 
surgical conversion if needed (50).  
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7. TRANS-FEMORAL TAVI 
 
TAVI using retrograde trans-femoral access represents the least invasive 
approach and is usually considered as the first choice since it can be performed 
completely percutaneously and with local anesthesia. Due to the large size (up 
to 24 Fr) of the initially available delivery sheaths, retrograde TAVI procedures 
were performed through the iliac artery using the so-called “iliac conduit 
technique”. Subsequent technological improvements resulted in smaller sheath 
profiles and led to the era of purely percutaneous access via the common 
femoral artery. This is achieved with the use of arterial “pre-closure” devices. A 
step-by-step approach is mandatory in order to minimize the risk of 
complications. The first step is to identify the puncture site, which should be 
above the femoral bifurcation in a segment without or with little calcification, 
and which can be identified by contrast agent injection from the contralateral 
access site. Then, the femoral artery is punctured under fluoroscopic guidance 
and a standard 0.035 inch wire introduced into the femoral artery. Following a 
1-2 cm skin incision and blunt dissection of the subcutaneous tissue with 
surgical clamps, a preclosure suture device is placed. The native aortic valve is 
retrogradely crossed and a J-shaped (in order to reduce the risk of ventricular 
perforation) extra-stiff wire (or super-stiff wire) is placed into the left ventricle. A 
temporary pacemaker is introduced via the femoral vein and positioned in the 
right ventricle. Balloon aortic valvuloplasty is then performed during rapid 
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pacing (160-220 bpm). Careful attention should be given to the movement of 
valve calcifications during balloon inflation, which may obstruct the ostium of 
the coronary arteries. Contrast agent injection in the aortic root during BAV 
enables assessment of coronary flow during balloon inflation and mimics valve 
implantation. After successful balloon dilation, the trans-catheter aortic valve 
delivery catheter is inserted and the bioprosthesis carefully advanced across the 
aortic arch. The balloon expandable bioprosthesis is deployed during rapid 
ventricular pacing, whereas self-expanding valve systems can be released from 
the delivery system without rapid ventricular pacing. After deployment, the 
correct positioning of the valve and the absence of aortic insufficiency are 
checked by means of angiography and echocardiography. The delivery systems 
and the sheaths are then removed and the femoral artery is closed with the 
preclosure device. The occlusion of the femoral artery with a balloon coming 
from the contralateral site before closure is useful since it allows tying sutures in 
a vessel that has no pressure thus reducing the risk of tears. The integrity of the 
aorto-iliac axis is then checked with angiography at the end of the procedure. 
Figure 16 shows the different steps of a TF-TAVI procedure with the balloon-
expandable Sapien valve.  
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_______________________________________________________________________________________________ 
Fig. 16. Procedural steps of TF-TAVI procedure with the Edwards Sapien balloon-
expandable device. A. A J-shaped extra-stiff  guide is placed in the left ventricle and the 
balloon catheter is retrogradely advanced through the aortic arch. B. Balloon aortic 
valvuloplasty is performed during rapid pacing. C. The delivery system with the prosthesis 
crimped on the balloon is placed in its f inal posit ion at the level of the aortic annulus. D. 
The balloon is inflated and the valve is deployed during rapid ventricular pacing. E. The 
valve prosthesis is correctly posit ioned and the delivery system together with the 
guidewire are retrieved. 
     A                          B                      C                       D                         E	  
	   34	  
8. TRANS-APICAL TAVI 
 
To date the most used device for trans-apical TAVI is the Sapien XT valve 
(Edwards Lifesciences, Irvine, CA, USA), which is a balloon expandable 
prosthesis whose leaflets are made of bovine pericardium mounted on a 
chrome-cobalt stent. New trans-apical devices with different technical features 
have been recently introduced into clinical practice: Jena-Valve (Jena-Valve 
Technology, Munich, Germany) and Acurate (Symetis, Lausanne, Switzerland). 
They are made of nitinol and are self-expandable. However, since these new 
devices are still in their initial clinical phase, this paragraph will describe the 
implantation technique of the balloon- expandable Sapien XT valve. Trans-
apical aortic valve implantation is usually performed under general anesthesia in 
a hybrid operating room if available, or in the catheterization laboratory. A mini 
anterior left thoracotomy is performed. The pericardium is opened and the left 
ventricular apex is exposed. A double purse-string suture is done on the 
muscular portion of the LV apex with Teflon pledgets reinforcement. Through a 
needle puncture of the LV apex in the central portion of the purse-string sutures 
a stiff guide-wire is passed through the native aortic valve and an introducer 
sheath is inserted in the left ventricle. This sheath will be used to introduce the 
balloon for the aortic valvuloplasty and the delivery system of the TAVI valve. A 
balloon aortic valvuloplasty is then performed during rapid pacing (160-220 
bpm). In the meanwhile the bioprosthesis is crimped on the balloon of the 
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delivery system. Once the bioprosthesis is advanced to its correct position (50% 
above and 50% below the plane of the aortic annulus) rapid pacing is started, 
the balloon is inflated and the valve is deployed. Since this is a balloon 
expandable device it is not retrievable after deployment, thus a correct 
positioning is mandatory. If the prosthesis is malpositioned, embolization in the 
LV or in the ascending aorta or a severe para-valvular leak can occur. Once the 
valve has been deployed the sheath is removed and purse-string sutures are 
tightened in order to achieve a reliable hemostatic closure of the LV apex. 
Angiographic and echocardiographic controls are always done in order to 
assess correct positioning and function of the bioprosthesis. Figure 17 shows 
the procedural steps of TA-TAVI 
 
                   A                              B                         C                           D 
	  ________________________________________________________________________________________________________________________________	  
Fig. 17. Procedural steps of TA-TAVI with the Edwards Sapien balloon-expandable device. 
A. A mini left anterior thoracotomy is performed. The left ventricular apex is exposed and 
two concentric purse-string sutures are placed on the muscular portion of the apex. B. An 
extra-stiff  wire is placed antegradely in the descending aorta through the aortic valve and 
balloon aortic valvuloplasty is performed during rapid pacing. C. The delivery system is 
advanced in the ventricular cavity and the valve is placed in its f inal posit ion in the aortic 
annulus. Valve deployment is done during rapid ventricular pacing. D. The valve 
prosthesis is correctly posit ioned and the delivery system together with the guidewire are 
retrieved. The ventricular apex is closed tying the sutures during rapid pacing. 
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9. TRANS-AORTIC TAVI 
 
Under general anesthesia, a small anterior thoracotomy is performed in the 
second intercostal space. After opening and suspension of the pericardium the 
ascending aorta is exposed. Two concentric purse-strings sutures are made as a 
conventional aortic cannulation. Puncture of the aorta is performed in the 
middle of the purse-string sutures and, under fluoroscopic guidance, an 
angiographic guide-wire is inserted retrogradely through the aortic valve in the 
LV. Since the direction of the guide-wire is not perpendicular to the plane of the 
aortic valve, particular attention should be given in order to avoid possible 
lesions to aortic sinuses and to the aortic wall. A 6F sheath is then placed on the 
guide-wire through the aortic valve in order to exchange the guide-wire with a 
J-shaped extra-stiff one that will be placed in the left ventricle, following the 
already described trans-femoral implantation technique (51). The sheath is 
inserted in the ascending aorta (Fig. 18 A) in order to perform subsequent 
balloon aortic valvuloplasty and valve deployment. Aortic valvuloplasty is 
carried out with a 20 mm balloon during induced ventricular tachycardia (160-
200 bpm) (Fig 18 B). The prosthesis is then placed in the correct position (50% 
below and 50% above the aortic annulus) and valve deployment is performed 
during rapid pacing (Fig. 18 C). Correct valve positioning and the absence of 
residual aortic valve regurgitation is confirmed by post-procedural aortic 
angiography (Fig 18 D) and by intraoperative trans-esophageal echo (Fig 18 E). 
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The sheath is then removed and aortic purse-string sutures are tightened. 
Trans-aortic TAVI can also be performed through mini sternotomy in 3rd or 4th 
intercostal space in a “J” or “inverted T” fashion. Figure 18 shows the 
procedural steps of Tao-TAVI. 
	  
_______________________________________________________________________________________________ 
Fig. 18. Procedural steps of TAo-TAVI with the Edwards Sapien balloon-expandable 
device. A. Double concentric purse string sutures are placed on the ascending aorta and 
the sheath is introduced after aortic puncture and guidewire insertion. B. Balloon aortic 
valvuloplasty is performed during rapid pacing. C. The valve is deployed during rapid 
pacing. D-E. Prosthesis posit ion and function are evaluated by means of aortic 
angiography and intraoperative trans-esophageal echo. 
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10. TRANS-SUBCLAVIAN/TRANS-AXILLARY TAVI 
 
This approach is generally carried out if none of the previously described 
accesses is feasible. It requires a surgical cut-down of the left subclavian artery. 
Under a technical point of view the procedure is identical to the already 
described trans-femoral TAVI. The pros of this approach are the relatively easy 
surgical access, the need for local anesthesia only and that the subclavian artery 
is usually not diseased. The drawbacks of subclavian TAVI are the risk of major 
bleeding, the unfavourable sharp 90 degrees angle to access the aortic arch 
(Fig. 19), and the risk of myocardial ischemia if a mammary artery to left anterior 
descending coronary artery graft is present.  
 
	  
 
 
 
__________________________________________________________________________________________________________________	  
Fig.  19.  Unfavorable sharp angles  of  TS-TAVI  	  
	   39	  
11. COMPLICATIONS OF TAVI 
 
TAVI should be considered in all respects a “true” surgical procedure and, as 
every surgical procedure, it should be performed with maximal safety. Safety is 
a major issue of TAVI, in fact it has been demonstrated that the occurrence of 
intraoperative complications significantly worsen patient outcomes (52). Rodes-
Cabau (53) indentified the need for peri-procedural mechanic hemodynamic 
support as an independent risk factor for 30-day mortality (OR: 6.84). In view of 
the strong impact played by intraoperative complications on patient early and 
late outcomes all efforts should be directed on preventing and effectively 
managing such occurrence. Prevention can be achieved by careful patient 
selection, adequate procedural planning (access choice, valve sizing) and 
execution. The successful management of intraoperative complications needs a 
strong synergy between physicians and the presence of life saving devices (the 
already described “safety net”) such as, for example, a cardiopulmonary bypass 
machine with a perfusionist technician in case of acute refractory cardiogenic 
shock or endovascular occlusion balloons if a damage to the aorta or to a 
peripheral vessel with severe hemorrhage occurs. TAVI complications are: 
arterial injury (rupture, dissection), apical access issues, improper positioning, 
device embolization, coronary obstruction, mitral valve injury, paravalvular 
regurgitation, cardiac tamponade, heart block, arrhythmias and stroke. In 
particular, TA-TAVI related complications are: bleeding, left ventricular pseudo-
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aneurism, loss of left ventricular function, left lung injury, pleural effusion, 
pneumothorax, infection of the thoracotomy (54-58). 
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12. CURRENTLY AVAILABLE TAVI DEVICES 
 
12.1 Edwards Lifesciences Sapien XT THV 
The Sapien XT valve is a balloon expandable prosthesis whose leaflets are 
made of bovine pericardium mounted on a chrome-cobalt stent. The cobalt-
chrome based stent frame allows for a more open stent design with fewer and 
thinner stent struts without loss of radial force. The Edwards Sapien XT trans-
catheter heart valve is commercially available in three sizes.  
 
1
______________________________________________________________________________________ 
Fig.  20.  Edwards Sapien XT sizing chart . TEE: trans-esophageal echo, CT: 
Computed tomography, MD: Mean diameter, BAV: Balloon aort ic valvuloplasty. 
2
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Small diameters of the aortic annulus ranging from 18–22 mm are treated with 
the 23 mm bioprosthesis, whereas annular dimensions ranging from 21–25 mm 
are treated with a 26 mm bioprosthesis. For large valve dimensions with an 
annulus measuring in the range of 24–27 mm, a 29 mm Edwards Sapien XT 
bioprosthesis can be used (59) (Fig. 20) 	  
 
The progressive development of 
smaller sheaths now allows to 
perform TF-TAVI in a higher 
number of patients. In fact in the 
new NovaFlex delivery catheter 
together with the new E-Sheath 
the labeled sheath size was 
reduced to 16 Fr for the 23 mm 
and 18 Fr for the 26 mm prosthesis. This means that the minimum vessel 
diameter for a safe TF approach is 6.5 mm for Sapien XT size 23 mm and 26 
mm and 7 mm for the 29 mm valve. In addition, Edwards will soon introduce 
the new Sapien 3 valve that is the evolution of Sapien XT. The Sapien 3 valve 
has a completely new design that includes a teflon skirt on the external part of 
the inflow portion of the valve that has the aim of increasing annular sealing 
thus reducing the incidence of paravalvular leaks. Furthermore the new design 
allows crimping on smaller catheters both for TF and for TA approach (Fig. 21). 
__________________________________________________ 
Fig.  21. The new Edwards  Sapien 3 trans-
catheter aortic  valve. This device features a 
teflon skir t on the external part of  the inf low 
portion that reduces the inc idence of  
paravalvular  leaks 
	   43	  
12.2 Medtronic Corevalve 
The Medtronic Core-Vale (Medtronic, Minneapolis, Minnesota, USA) uses self-
expanding technology and anchors the bioprosthesis in the supra-annular 
position. The frame is made of Nitinol, which has a shape memory and provides 
high radial forces. The Nitinol frame, with a single layer of porcine pericardium, 
can be crimped down to a delivery sheath size of 18 Fr for all valve sizes (23–31 
mm). The frame is obtained by laser cutting and generates a high radial force at 
the distal part of the frame, which serves to anchor the prosthesis within the 
annulus. The mid-portion of the prosthesis has a concave shape in order to 
avoid contact with the sinus portion and the origin of the coronary arteries. The 
proximal part is placed in the ascending aorta and helps to position the 
prosthesis perpendicular to the native valve. Compared with the balloon-
expandable Edwards Sapien trans-catheter valve prosthesis, there is no 
additional material serving as coverage of the bioprosthesis. The pericardial 
tissue used to build the three leaflets also serves to form a sealing skirt at the 
bottom part of the frame. With the latest CoreValve generation (third 
generation CoreValve, 18 Fr) four different valve sizes are commercially 
available to cover a broad range of annulus dimensions: small aortic annulus 
diameters ranging from 18–20 mm are treated with a 23 mm CoreVave Evolut 
prosthesis, annulus diameters ranging from 20–23 mm require a 26 mm 
CoreValve prosthesis, annulus diameters ranging from 23–27 mm require a 29 
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mm prosthesis, while annulus diameters in the range of 26–29 mm are treated 
with a 31 mm CoreValve bioprosthesis (Fig. 22).  
 
	  ________________________________________________________________________________________________________________________________	  
Fig. 22. Medtronic CoreValve sizing chart. TEE: trans-esophageal echo, CT: Computed 
tomography, MD: Mean diameter, BAV: Balloon aortic valvuloplasty, CoV: CoreValve, 
AsAo: Ascending aorta. 	  
The Medtronic CoreValve prosthesis is designed for retrograde implantation 
through femoral access, but has also been successfully implanted through the 
subclavian artery or using a trans-aortic approach (60).  
 
12.3 Symetis Acurate 
Newer generation devices have been designed to improve precise positioning 
of the prosthesis, enable re-positioning in case of unsatisfactory deployment, 
and full retrieval whenever needed to improve patient safety and increase 
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procedural success. Recently, the Symetis Acurate TA trans-catheter heart valve 
(Symetis, Lausanne, Switzerland) prosthesis was introduced as a new-generation 
TAVI device (61). The Symetis Acurate prosthesis has self-expanding Nitinol 
stent frame and a porcine biologic aortic valve. The stent frame has three 
different segments. The lower segment is tapered and flared in order to provide 
appropriate fixation within the aortic annulus due to the radial force of the 
Nitinol. The distal part of this stent segment is covered with PET (polyethylene 
terephthalate) tissue creating a sealing skirt. The middle segment contains the 
valve apparatus and three stabilization arms, which form the upper segment of 
the valve frame. After preparation of the Acurate 
valve and delivery catheter the device is directly 
inserted into the left ventricle over a stiff wire in 
the absence of a delivery sheath. After advancing 
the trans-catheter valve system through the 
native aortic valve, all cusps are aligned with the 
normal anatomical position by manual rotation of 
the catheter. Stepwise release of the stabilization 
arms by rotation of the pullback mechanism opens 
the upper crown and provides fixation of the 
bioprosthesis in the ascending aorta. By gently pulling on the catheter, the 
Symetis Acurate TA is placed within the aortic annulus and, during a short 
period of rapid ventricular pacing, fully released by further unsheathing the 
_________________________________________	  
Fig.  23. Symetis Acurate TA 
trans-catheter aortic valve 
and its si zing chart.  
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system. It might be a valuable alternative treatment option for patients with 
trans-apical access who are not suitable candidates for the balloon-expandable 
device (e.g. patients with heavily calcified native valves or low distance to the 
coronary ostia). Devices are available in three different sizes to treat patients 
with aortic annulus dimensions ranging from 21–27 mm. Using the 23 mm 
bioprosthesis, small aortic annulus dimensions ranging from 21–23 mm are 
treated, whereas the 25 mm prosthesis is suitable for annulus dimensions 
ranging from 23–25 mm, and the 27 mm prosthesis requires annulus 
dimensions ranging from 25–27 mm (Fig. 23). 
 
12.4 Jena-Valve 
The Jena-Valve trans-catheter heart valve device consists of a Nitinol-based 
stent frame with a regular porcine tissue valve (Elan, Vascutec Inc, Inchinan, UK). 
The stent design includes three dedicated 
positioning ‘feelers’, which facilitate appropriate 
positioning of the prosthesis. The outer part of 
the device is covered with a sealing skirt of 
porcine pericardial tissue to reduce the 
incidence of paravalvular regurgitation. At this 
point in time the Jena-Valve bioprosthesis is 
exclusively implanted via the trans-apical access 
route. After passing the native valve antegradely through a delivery catheter 
____________________________________________	  
Fig. 24. Jena-Valve trans-
catheter aortic  valve and its 
sizing chart . 
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hosting the crimped bioprosthesis, without the need for a sheath, the three 
feelers are released in the supra-annular position. By manual manipulation of 
the catheter an alignment according to the anatomy of the aortic sinus is 
achieved, thereby embracing the native aortic cusps. During a short period of 
rapid ventricular pacing the Jena-Valve is then released. The native aortic valve 
is clipped within the feelers and the base of the stent frame. The radial 
expansion force of the self-expandable stent frame allows a complete 
displacement of the degenerated native valve cusps and stable fixation in a 
sub-coronary position. Currently three different valve dimensions are 
commercially available to cover a wide range of aortic annulus dimensions (23 
mm, 25 mm and 27 mm) (Fig.24). 
 
12.5 St. Jude Portico 
The Portico Trans-catheter Aortic Valve Implantation System (St. Jude, 
Minneapolis, MI, USA) has recently received the CE mark for the treatment of 
patients with aortic valve stenosis. It has a self-expandable nitinol frame with 
bovine pericardium valve leaflets and porcine pericardium sealing cuff (Fig. 25). 
At this point in time the Portico bioprosthesis is exclusively implanted via the 
trans-femoral access route. The trans-apical delivery is under its final 
development stages. The outflow portion of the stent frame incorporates 3 
retention tabs, which secure the crimped valve to the delivery system. The 
Portico valve is sized according to the nominal external stent diameter at the 
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______________________________________________	  
Fig.  25.  St . Jude Medical Port ico 
trans-catheter valve 	  
valve level. Currently, only the 23-mm device is 
available. The catheter consists of a soft 
tapered nose cone, an 18F capsule that 
contains the compressed valve, and a 12F 
shaft. A handle incorporates mechanisms to 
unsheathe and release the valve using a 
rotating thumbwheel.  
 
12.6 Direct Flow 
The Direct Flow Trans-catheter Aortic Heart Valve System (Santa Rosa, CA, USA) 
has a metal-free frame and bovine pericardial leaflets. The Direct Flow Medical 
System incorporates a polymer frame, which is expanded using pressurized 
saline and contrast for placement, assessment and repositioning. The 
saline/contrast solution is exchanged for a quick-curing polymer that solidifies 
and secures the valve in place once optimal positioning is reached. The system 
is fully repositionable and retrievable 
until polymer exchange. The metal-free 
design enables a low-profile (18 
French), fully sheathed delivery system 
for all valve sizes  (Fig.26). The device 
comes in two sizes: 25 mm and 27 mm 
_________________________________________________________	  
Fig.  26. Direct Flow trans-catheter 
aort ic valve. 	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that cover annulus diameters from 19 to 24 mm and from 24 to 26,5 mm, 
respectively. The first results of the DISCOVER trial, a prospective multicenter 
study that included 100 patients were recently presented at the 2013 Euro-PCR 
meeting by Joachim Schofer. These results include only procedural and 30-day 
assessment of patients. Thirty-day mortality was 1% (1 patient), device success 
(according to the Valve Academic Research Consortium –VARC- definitions) was 
91%, and combined safety endpoint (VARC) was 89%. Post-procedure aortic 
regurgitation ≤mild was found in 99% and mean trans-aortic gradient was 14 
mmHg. These results are encouraging but longer follow-up and larger cohorts 
are required to fully understand the behavior of this device. 
 
12.7 Medtronic Engager 
The Engager bioprosthesis (Medtronic 3F Therapeutics, Santa Ana, CA) consists 
of bovine pericardium leaflets mounted on a nitinol stent. Its current version 
uses a 29F system (32F crossing profile) for trans-apical delivery. During 
implantation, the control arms that capture the native 
leaflets are released and allow for tactile feedback 
during anatomically correct placement of the valve at 
a predefined height within the aortic annulus. The 
lower part of the nitinol stent is covered and formed 
to have the potential for better sealing of 
___________________________________	  
Fig.  27.  Medtronic  
Engager trans-catheter 
valve 	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paravalvular leaks (Fig. 27). The intermediate follow up results from the 
multicenter Engager European pivotal trial have been recently published 
(December 2013) in the Annals of Thoracic Surgery. Data show that for all of the 
attempted implantations (n = 60), the Engager prosthesis was positioned in the 
correct anatomic position without conversions to surgery, second valve 
implantation, device malposition, aortic annular rupture, or coronary 
obstruction. All-cause mortality was 9.9% at 30 days and 16.9% at 6 months. 
The baseline mean aortic valve gradient was 43.7 ± 16.7 mm Hg and 11.5 ± 5.0 
mm Hg at 30 days, and showed similar reduction at 6 months (13.9 ± 6.2 mm 
Hg). There was no paravalvular regurgitation greater than mild through 6 
months (62).  	  	  
12.8 Boston Scientif ic Lotus  
 
The Lotus™ Aortic Valve Replacement System 
(Boston Scientific Corporation, Natick, MA, USA) 
includes a bioprosthetic aortic valve implant 
consisting of three bovine pericardial leaflets 
attached to a braided nitinol frame with a 
radiopaque marker and a catheter-based system 
for introduction and retrograde delivery via the 
femoral artery (Fig. 28). The valve is pre-attached 
to the delivery system. The Lotus Valve starts working early in deployment, 
______________________________________	  
Fig.  28.  Boston Scientif ic 
Lotus trans-catheter heart  
valve.  	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aiding controlled, precise initial positioning, and repositioning or full retrieval at 
any point prior to definitive release if required. Rapid pacing is not required 
during the implant procedure. The valve is designed to expand radially as the 
valve shortens during deployment. An adaptive seal surrounds the inflow 
portion of the device and is designed to reduce paravalvular regurgitation. The 
REPRISE I study (63) evaluated results of Lotus valve implantation in 11 patients.  
The primary endpoint (clinical procedural success) included successful 
implantation without major adverse cardiovascular or cerebrovascular events 
(MACCE). In all patients the first Lotus valve was successfully deployed. Partial 
resheathing to facilitate accurate placement was attempted and successfully 
performed in four patients; none required full retrieval. The primary endpoint 
was achieved in 9 out of 11 patients with no in-hospital major adverse cerebral 
and cardiovascular events. The cohort’s mean aortic gradient decreased from 
53.9±20.9 mmHg at baseline to 15.4±4.6 mmHg (p<0.001) at one-year; valve 
area increased from 0.7±0.2 cm2 to 1.5±0.2 cm2 (p<0.001). Discharge 
paravalvular aortic regurgitation was absent, trivial and mild in 8, 1 and 2 
patients, respectively. There were no deaths, myocardial infarctions or new 
strokes through one year. 
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13. INDICATIONS AND CONTRAINDICATIONS FOR TAVI 
 
According to 2012 European Society of Cardiology/European Association of 
Cardio-Thoracic Surgery guidelines on the management of valvular heart 
disease (13) surgical aortic valve replacement is indicated in symptomatic 
patients with aortic valve area < 1cm2 and mean trans-aortic gradient >40 
mmHg  (Fig.  29).  
 
	  
_______________________________________________________________________________________________ 
Fig. 29. Indications for aortic valve replacement in aortic stenosis according to the 
guidelines issued in 2012 by the European Society of Cardiology 
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TAVI is recommended in patients with severe symptomatic AS who are, 
according to the ‘heart team’, considered unsuitable for conventional surgery 
because of severe comorbidities (Fig. 30).  
 
	  ________________________________________________________________________________________________________________________________	  
Fig. 30. Management of severe symptomatic aortic valve stenosis according to the 
guidelines issued in 2012 by the European Society of Cardiology 
 
	   54	  
Among high-risk patients who are still candidates for surgery, the decision 
should be individualized. TAVI should be considered as an alternative to surgery 
in those patients for whom the ‘heart team’ prefers TAVI, taking into 
consideration the respective advantages/disadvantages of both techniques. A 
logistic Euro-SCORE ≥20% and/or STS mortality score≥10% have been 
suggested as cut-off values for TAVI. However, these scores were not 
developed nor validated in a high-risk elderly population. Thus caution should 
be used in their use as the only indication for TAVI.  Other important conditions 
such as porcelain aorta, frailty, previous cardiac operations, hostile chest, and 
chest radiation should lead to schedule a patient for TAVI even if risk scores are 
not particularly high. The PARTNER II trial (64), that is still ongoing at the 
present time, is enrolling patients with an intermediate risk profile (STS mortality 
score >4%) and will probably tell us if TAVI indications can be expanded to 
patients with lower risk profile. To date, the issues that are still partially 
unsolved and that have limited TAVI diffusion to intermediate risk patients are 
mainly related to post-procedural paravalvular leaks and to valve durability. 
Paravalvular leak occurs in many patients after TAVI (65). Main causes of 
paravalvular leak are: wrong selection of the size of the device, malposition and 
bulky eccentric calcification (66-68). There is clear evidence that at least 
moderate paravalvular leak has a significant impact on survival. On the other 
hand, there is conflicting evidence about the impact of mild paravalvular leak on 
survival. Results from the PARTNER trial show that the presence aortic 
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regurgitation (mild, moderate, or severe vs. none or trace) after TAVI is 
associated with increased late mortality (hazard ratio, 2.11; 95% CI, 1.43-3.10; 
P<0.001) (69). Furthermore, the effect of aortic regurgitation on mortality seems 
to be proportional to the severity of the regurgitation (Fig. 31), but even mild 
aortic regurgitation is associated with a reduced long-term survival.  
 
	  
_______________________________________________________________________________________________ 
Fig. 31. Relation of aortic regurgitation to all-cause mortality in the TAVI population. Data 
from the PARTNER trial (69) 
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Different results are observed when looking at “real world” registries like the 
German Aortic Valve Registry (GARY) and the FRANCE 2 TAVI Registry.  The 
latter (70) shows that patients with post-procedural paravalvular leak grade 1 
(mild) have exactly the same mortality 
rate than patients with absent 
regurgitation (i.e. 10% all-cause mortality 
at 1 year) while patients with at least 
grade 2 (moderate and severe) 
Paravalvular leak (PVL) have significantly 
worse 1 year outcomes (25% all-cause 
mortality at 1 year, p<0.001), independently from the implanted valve-type(Fig. 
32-33).  
Same results are visible when looking at data from the German registry (71-
73) where patients with none or mild post-TAVI PVL have 82% survival at 1 
_________________________________________________________	  
Fig.  32.  One year actuaria l mortality 
according to post-procedural aort ic 
regurgitat ion.  Data f rom the FRANCE 2 
registry 
________________________________________ 
Fig.  33. Impact of paravalvular  
regurgitat ion on one-year mortality 
according to valve type. Data f rom the 
FRANCE 2 registry 	  
______________________________________________________________	  
Fig.  34. One-year actuar ial mortality  
according to post-procedural aortic 
regurgitat ion.  Data from the German Aortic  
Valve Registry 
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year versus 71% survival of patients with at least moderate PVL (p<0.001)      
(Fig. 34).  
However, it is likely that improvements in valve design as well as in procedural 
planning and performance will lead to a significant decrease in the rate of PVL. 
If we look at valve durability, data on long-term behavior of TAVI devices are 
still lacking since TAVI growth and diffusion is relatively recent. Longer follow up 
until time points when valve related adverse events are more likely to occur is 
mandatory. Early structural valve deterioration is a theoretical concern with TAVI 
since the long-term durability of trans-catheter valves is still unknown. The 
Edwards Sapien valve is constructed of the same bovine pericardial tissue that 
has been treated with the same fixation and decalcification processes as the 
surgical valves, and has the same durability performance by accelerated wear 
“in vitro” testing. However, we cannot assume that the durability of trans-
catheter valves will be the same as surgical valves for several reasons: different 
design resulting in differing shear forces on the tissue, use of thinner pericardial 
tissue and above all the crimping process that may cause tissue damage (74, 
75). To date there has been no substantive reports of early structural valve 
deterioration with trans-catheter valves. No cases of operation for structural 
valve deterioration or changes in aortic valve area and mean trans-valvular 
gradients were reported in the PARTNER trial at 2 years (69). Obviously 
experience is too limited to date, with only a small number of patients having 
intermediate term follow-up, to make statements with any degree of assurance 
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regarding long-term durability. However, it is reassuring that until now structural 
valve deterioration has not been an issue. This issue will assume greater 
importance though as TAVI experience expands into lower risk and younger 
patients with longer life expectancy. Whereas the mean life expectancy in the 
current TAVI treated population is 5–7 years, some greater assurance of long-
term durability is necessary before significant further expansion occurs. It should 
also be remembered that with surgically implanted valves, there is decreased 
valve durability in younger ages and one can assume that trans-catheter valves 
will follow the same pattern. 
Always according to ESC/EACTS guidelines (13), TAVI should only be 
performed in hospitals with cardiac surgery on-site. Contraindications, both 
clinical and anatomical, should be identified and are shown in figure 34.  
	  
________________________________________________________________________________________________________________________________	  
Fig. 34. Contraindications for TAVI according to the guidelines issued in 2012 by the 
European Society of Cardiology 
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Eligible patients should have a life expectancy of more than 1 year and should 
also be likely to gain improvement in their quality of life, taking into account 
their comorbidities. Contraindications for TF-TAVI are mainly related to aorto-
iliac vessels diameters, tortuosity and extent of calcifications. Furthermore, 
extremely tortuous vessels represent a 
contraindications as well as the presence of 
circumferential calcifications in arteries with 
borderline diameters that make vessels 
completely rigid and non-compliant. The 
presence of atherosclerotic plaques in the 
aortic arch, especially if at the origin of supra-
aortic vessels may represent another 
contraindication to TF-TAVI for the risk of 
plaque disruption and consequent cerebral 
embolization. Contraindications to TA-TAVI are severe left ventricle dysfunction 
with an ejection fraction <20% and the presence of LV aneurysm with thrombus 
stratification. Relative contraindications to TA-TAVI are represented by chest 
deformities and severe chronic obstructive pulmonary disease (COPD). The 
presence of diffuse calcifications on the ascending aorta is the main 
contraindication for Tao-TAVI. Relative contraindications for Tao-TAVI are 
represented by chest deformity, COPD and previous cardiac operations. If a 
______________________________________________	  
Fig.  35.  Preoperative CT scan of  
a patient scheduled for Tao-
TAVI . Less than 50% of the 
ascending aorta i s placed 
r ightward with respect to the 
r ight sternal edge (yellow sign).  
Thus, this pat ient would be 
better t reated with a mini-
sternotomy rather than a mini  
r ight thoracotomy. 
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Tao-TAVI through mini right thoracotomy is scheduled, particular attention 
should be given to the position of the ascending aorta with respect to the right 
sternal edge. If the aorta is placed more than 50% rightward, then the access to 
the aorta will be easy and straightforward. On the other hand, if the aorta is 
more medial, its approach through right thoracotomy may be more challenging 
and a mini-sternotomy is therefore suggested (Fig. 35) (76, 77). 
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14. PREOPERATIVE IMAGING 
 
A careful and complete evaluation of patient’s clinical history, general 
conditions and diagnostic imaging examinations is mandatory for good TAVI 
outcomes. As every cardiac operation, TAVI requires a complete preoperative 
screening that includes: cardiac catheterization (with coronary artery 
angiography, aortic angiography, left ventriculography, right and left pressures 
measurement), echocardiography, complete arterial Doppler study, pulmonary 
function evaluation and blood exams. In particular, imaging screening may 
orient physicians in the choice of the most suitable TAVI device as well as 
access route for each single patient according to his specific anatomic 
characteristics. Furthermore, appropriate preoperative imaging allows a precise 
selection of the size of the chosen device. This chapter will focus on imaging 
screening examinations that are specific for patients scheduled for TAVI. 
 
14.1 Echocardiography 
To assess the size and type of device 
and reduce the risk of events, a 
complete imaging dataset is essential 
(Fig. 36) (78).  
The most frequent etiology in TAVI 
patients is calcific degenerative disease. ____________________________________________________________	  
Fig.  36. Imaging dataset required for 
preoperat ive evaluation before TAVI (78). 
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However, it is important to evaluate if the patient has a bicuspid valve because 
this may preclude TAVI or make procedural success less likely due to 
asymmetric distribution of leaflets and of annular calcifications (79). In calcific 
degenerative disease, thickening starts at the base of the cusps and progresses 
towards the leaflets. In tricuspid valves, the assessment of calcium distribution 
on each leaflet is important because this may predict potential coronary ostia 
occlusion during deployment. The diameter of the ‘echocardiographic annulus’ 
is a key measurement in determining if TAVI can be performed and what should 
be the size of the device. In fact, undersizing may cause paravalvular leak and 
also device embolization (80) while oversizing can cause rupture of the annulus 
that is generally fatal (81). The annulus diameter should be measured at the 
hinge point between the base of the anterior mitral leaflet and the adjacent 
aortic cusp in a systolic frame with maximal leaflet separation. Since the annulus 
_____________________________________________________________________________________________________________________________	  
Fig.  37. Anatomic and bidimens ional echocardiographic  view of human aortic root.  
Echocardiographic measurement does not transect the full diameter of the annulus 
(blue arrow) but takes into considerat ion a shorter cut (red arrow) (1).  
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shape is also often slightly ellipsoidal rather than circular, it is usually 
underestimated by transthoracic echocardiography (TTE) and trans-esophageal 
echocardiography (TEE) (82-83) (Fig. 37).  
 
Thus preoperative or intraoperative 3D TEE is generally recommended. Other 
than for the measurement of annulus diameter, echocardiography is also 
important for left ventricle, mitral valve and right ventricle assessment. A careful 
examination of the left ventricular outflow tract, and in particular the evaluation 
of septal bulging, may help to prevent severe complications and to guide the 
choice of the device size. Furthermore, measurement and morphologic 
evaluation of the aortic root and of the sino-tubular junction (STJ) is another 
important step in procedural planning. In the presence of a borderline annulus, 
which may accept either a small or a big device, if aortic sinuses are narrow and 
STJ is small, the smaller device should be chosen. During a TA-TAVI operation, 
intraoperative TEE is helpful to find the correct apical site where to place 
sutures and to insert the sheath. 
 
14.2 Computed Tomography Scan  
As opposed to conventional aortic valve replacement, physicians performing 
TAVI have only a “virtual” visualization of the aortic valve. As a result, imaging is 
necessary to allow for appropriate valve sizing. CT scan is now becoming the 
“gold-standard” preoperative diagnostic evaluation for TAVI planning. The 
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information that CT scan is able to provide is mainly related to: three-
dimensional reconstruction of the aortic annulus and measurement of 
diameters, perimeter and area of the annulus, distance of the annulus from the 
coronary ostia, length of the aortic valve leaflets, distribution of calcium on the 
annulus and on the leaflets, evaluation of the best access pathway, assessment 
of the appropriate fluoroscopic projection angles that permit exactly orthogonal 
views of the valve (84). Image acquisition remains challenging, however, since a 
large imaging volume needs to be covered from the aortic arch to the 
bifurcation of the femoral arteries. The volume of iodinated contrast medium is 
of concern in many patients because candidates for TAVI frequently have 
chronic kidney disease. Given the commonly advanced age of patients being 
considered for TAVI, radiation exposure is of lesser concern. Imaging of the 
aortic root must be synchronized to the electrocardiogram. Spatial resolution 
must be high to provide adequate imaging, especially of the aortic root and of 
the ilio femoral arteries, because in both regions detailed dimensions must be 
obtained to adequately plan the procedure. Choosing the appropriate 
prosthesis size requires accurate measurement of the dimensions of the aortic 
annulus. Measurements of aortic annulus size have historically been performed 
with TTE and TEE. It has been demonstrated that CT-scan based sizing provides 
larger aortic annulus dimensions if compared to echography. There are many 
studies that demonstrate that the use of CT-scan for sizing provides more 
reliable data and consequently improves TAVI outcomes (85-90). When 
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assessing the aortic annulus with CT-scan there are three measurements that are 
suggested by the guidelines: mean diameter, area and circumference.  
 
 
	  
________________________________________________________________________________________________________________________________	  
Fig. 38. Measurement of the aortic annulus diameter using CT scan. A. The optimal plane 
includes the three lowest insertion points of the coronary cusps (arrows). B. The short and 
long annulus diameters are measured and the mean diameter in calculated. C. The 
annulus area is measured and the mean diameter is derived assuming circularity of the 
annulus. D. The perimeter of the annulus is measured and the mean diameter is derived 
assuming circularity of the annulus. 
Besides aortic annulus size, other anatomic measures of the aortic root have 
relevance for TAVI planning. They include distance of the coronary ostia from 
the aortic valve plane, aortic cusp length, width of the aortic sinus, width of the 
sino-tubular junction, and width of the ascending aorta. These measurements 
are important in order to predict potentially catastrophic complications such as 
coronary occlusion and root injury. It has also been demonstrated that severity 
and pattern of distribution of calcium on the aortic annulus and valve leaflets, 
identified with CT scan, correlate with the presence and with the severity of 
postoperative paravalvular leak. (91). 
              A                          B                              C                             D 
	   66	  
15. THE PARTNER TRIAL 
 
The PARTNER (Placement of Aortic Trans-catheter Valves) trial is the first and to 
date the only prospective randomized trial studying outcomes of TAVI. The 
PARTNER trial was designed as a multicenter randomized trial comparing open 
standard aortic valve replacement (AVR) with TAVI in high-risk patients, and also 
TAVI versus standard medical treatment (47-49, 69). In addition, cost analysis, 2-
year data analysis, and stroke analysis have been done, as well as analysis of 
continued access for TA-TAVI (48, 69, 92, 93). Briefly, PARTNER A patients were 
required to be high risk for conventional open valve surgery (49, 69). This was 
determined by a minimal Society of Thoracic Surgeons (STS) score of 10% for 
death, and the surgeons’ assessment of the risk as >15%. For PARTNER B (47, 
48) patients approved for the study were required to have 2 cardiac surgeons 
agree that they were inoperable based on a combined risk of death and 
irreversible severe morbidity >50%. The device used for this trial was the 
Edwards Sapien balloon-expandable valve. The design of the PARTNER trial is 
shown in figure 39. 
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________________________________________________________________________________________________________________________________	  
Fig. 39. PARTNER trial design. AVR: Aortic valve replacement, TAVR: Trans-catheter aortic 
valve replacement, TF: Trans-femoral, TA: Trans-apical 
 
15.1 PARTNER A 
For PARTNER A, the trial was designed for non-inferiority of TAVI versus open 
AVR. In the PARTNER A arm, 351 patients were assigned to AVR and 348 to 
TAVI, of whom 244 were TF-TAVI and 104 TA-TAVI (69). Thirty-day mortality for 
intention to treat for was 3.4% for TAVI and 6.5% for AVR (p=0.07); for TF-TAVI, 
mortality was 3.3% versus 6.2% with AVR (p=0.13). For TA-TAVI, 30-day 
mortality was 3.8% and control AVR was 7.0% (p=0.32). At 1 year, mortality was 
24.2% for TAVI and 26.8% for AVR, with no significant difference; therefore the 
non-inferiority endpoint was met. Prevalence of neurologic events for TAVI 
versus AVR at 30 days was 5.5% versus 2.4% (p=0.04); prevalence of major 
strokes was 3.8% versus 2.1% (p=0.2). For all neurologic events, TF-TAVI versus 
open AVR was 4.6% versus 1.4% (p=0.05).  
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15.2 PARTNER B 
For PARTNER B the trial was designed to meet superiority of TAVI versus 
optimal medical management (including balloon aortic valvuloplasty). The 
primary endpoint was death or rehospitalization at one year. In PARTNER B (47, 
48), 358 patients were enrolled, and baseline variables were mostly well 
balanced. At 30 days after randomization, TAVI mortality was 5.0% and control 
was 2.8% (p=0.61) while at 1 year the mortality was 30.7% for TAVI and 50.7% 
for control. For the primary end point, death or rehospitalization, TAVI was also 
superior to control (p<0.001) and therefore the primary endpoint was met.  
Two-year data analysis of PARTNER A and Bconfirmed the two previous reports, 
but also added further information on late outcomes concerning stroke and 
paravalvular leaks. In particular, the update of PARTNER A showed an additional 
32 TAVI deaths and 25 AVR deaths, with no difference at 2 years (33.9% and 
35%, respectively, p=0.78). 
 
The analysis of paravalvular regurgitation of the PARTNER trial is particularly 
interesting. The incidence of moderate and severe PVL at one year was 7% and 
1,9%, respectively (p<0,001). At two years the incidence of moderate and 
severe PVL was 6.9% and 0.9%, respectively (p<0.001). As described in a 
previous paragraph, paravalvular or total aortic regurgitation after TAVI was 
associated with worse survival (p<0.001), and even mild regurgitation increased 
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mortality.The detailed analysis of stroke after TAVI or AVR in PARTNER A 
showed that 51% of strokes were procedure related, and 38% occurred within 2 
days: 43% of patients ultimately died (94). Analysis by procedure showed that 
for neurologic events (1.4% at 30 days), open AVR had the lowest risk followed 
by TF-TAVI (4.6% at 30 days; p=0.05), then group non-TF, with no difference 
between TA-TAVI and open AVR. Overall, for both TAVI and open AVR, the 
early multivariable predictors of neurologic events were TAVI versus open AVR, 
pre-procedure cerebrovascular disease, and smaller indexed native aortic valve 
area. The late hazard phase predictors were TAVI versus open AVR, higher New 
York Heart Association class, stroke within 6 to 12 months, non-TF-TAVI group, 
with less risk with previous percutaneous coronary intervention, and COPD.  
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16. VARC DEFINITIONS 
 
When reporting data and results on a particular procedure it’s important that 
studies speak the same language in order to be comparable and to make 
further analysis easier and reliable. To achieve this target, the Valve Academic 
research Consortium has published in 2011 “Standardized Endpoints 
Definitions for Trans-catheter Aortic Valve Implantation Clinical Trials” (95). This 
paper, updated in 2012 (96), aims to propose standardized consensus 
definitions for important clinical endpoints in TAVI investigations in order to 
improve the quality of clinical research and to enable meaningful comparisons 
between clinical trials. Consensus criteria were developed for the following 
endpoints: mortality, myocardial infarction, stroke, bleeding, acute kidney 
injury, vascular complications, and prosthetic valve performance. Composite 
endpoints for TAVI safety and effectiveness were also recommended. Safety is 
characterized by the avoidance of device related or procedural complications. 
Effectiveness is a more complex descriptor, as it encompasses both the 
avoidance of negative disease-related outcomes and objective measures of 
clinical functional benefit.  
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17. THE ITALIAN REGISTRY OF TRANS-APICAL AORTIC VALVE 
IMPLANTATION: THE I-TA REGISTRY 
 
Trans-apical aortic valve implantation is generally considered as a second 
choice after trans-femoral TAVI because it requires general anesthesia, left 
thoracotomy and manipulation of the left ventricular apex. Thus, many centers 
follow a trans-femoral first policy, meaning that trans-apical access is performed 
only when the trans-femoral one is not feasible due to narrow and/or tortuous 
aorto-iliac vessels. The ratio between trans-femoral and trans-apical procedures 
is generally 3:1 and consequently the number of TA-TAVI performed yearly at 
each center is limited. The rationale behind the development of a TA-TAVI 
Italian National Registry was to collect data from all patients who underwent TA-
TAVI in Italy in order to create a large common database with hundreds of 
patients coming from several different centers. The advantages of such project 
are mainly related to the large number of patients that make statistical analysis 
and results more reliable. The idea was born during spring of 2010 at the 
Division of Cardiac Surgery of the University of Padova, Italy. The aim was to 
create a prospective spontaneous, independent and multicenter registry. 
Spontaneous means that this project was not required by any institution or 
private company. Independent means that there are no industries that finance 
our registry thus eliminating the impact of potential conflict of interests. We also 
aimed at including all cases already performed in Italy since this procedure 
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became available in 2008. Data from 2008 to 2010 are therefore collected 
retrospectively while since 2011 data are prospectively collected. Data are 
collected at each center and then sent to the Division of Cardiac Surgery of 
Padova for storage and analysis. The first result of this project was an abstract 
submitted to the 2011 American Association of Thoracic Surgery (AATS) Annual 
Meeting that was accepted as oral presentation; the full manuscript was then 
published on the Journal of Thoracic and Cardiovascular Surgery in 2011 (65).To 
date there are 774 patients enrolled since April 2008 through June 2012 
coming from 21 cardiac surgery Italian centers. 
In this thesis we are proud to present the two most prestigious studies 
originated from the I-TA registry. 
The first study, entitled “Medium Term Outcomes Of Trans-apical Aortic Valve 
Implantation: Results From The I-TA Registry “ presents the most recently 
updated results from the registry and analyses medium term outcomes of 
patients undergoing TA-TAVI. This study was presented at the 2013 Society of 
Thoracic Surgeons (STS) Annual Meeting and published in the Annals of 
Thoracic Surgery in 2013 (97).  
The second study is a comparison between three different treatment options for 
patients suffering from severe symptomatic aortic valve stenosis: TA-TAVI, 
Conventional AVR and Sutureless aortic valve replacement. This study, entitled 
“Conventional Surgery, Sutureless Valves And Trans-Apical Aortic Valve 
Replacement: What Is The Best Option In Patients With Aortic Valve Stenosis? A 
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Multicenter, Propensity-Matched Analysis” was presented at the 2013 AATS 
Annual Meeting in Minneapolis and subsequently published in the Journal of 
Thoracic and Cardiovascular Surgery in 2013 (98).  
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18. MEDIUM TERM OUTCOMES OF TRANS-APICAL AORTIC VALVE 
IMPLANTATION: RESULTS FROM THE I-TA REGISTRY  
 
Aim of this prospective, multicenter, study was to examine clinical and 
hemodynamic outcomes of patients undergoing TA-TAVI. 
 
18.1 Patients and Methods 
From April 2008 through June 2012, 774 patients underwent TA-TAVI at 21 
centers and were enrolled in the I-TA registry. Appendix 1 shows the number of 
cases enrolled yearly in each center. Data collection was approved by the ethics 
committee and patient informed consent was always obtained. The dataset of 
the I-TA registry has been implemented according to the Valve Academic 
Research Consortium (VARC) updated definitions and endpoints (VARC-2) 
(95,96). Main indication for TA-TAVI was severe symptomatic aortic valve 
stenosis (Aortic valve area <0,8 cm2, mean trans-aortic gradient >40 mmHg) 
associated to one or more of the following: a) porcelain aorta, b) high surgical 
risk (Logistic Euroscore I >20%, Society of Thoracic Surgeons mortality score 
>10%), c) other serious comorbidities that advise against the surgical approach 
as: severe pulmonary disease, previous total chest irradiation, hostile chest, 
severe liver disease. The majority of centers that participate to the I-TA registry 
adopt a “trans-femoral first” policy. TA-TAVI procedures were performed 
usually under general anesthesia and the only implanted devices were the 
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Sapien and, since mid-2010 the Sapien XT pericardial balloon expandable 
bioprosthesis (Edwards Lifesciences, Irvine, CA, USA). Preoperative risk factors 
were defined according to the European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) (99). The recently updated VARC definitions were used 
to report safety and efficacy endpoints, valve performance and complications 
(96). The impact of learning curve on patient outcomes was analyzed by 
comparing the overall survival of the first 50% versus the second 50% of 
patients for each center. The impact of case-volume on survival was analyzed by 
comparing survival of centers with more than 27 cases versus centers with less 
than 27 cases. We adopted 27 cases as the cut-off value since this was the 
median number of cases performed in the participating centers.Patients 
underwent clinical and echocardiographic evaluation at their study site before 
the procedure, at discharge, between 2 and 6 months after TAVI and 12 months 
thereafter. Patients who were not able to reach the study site for clinical 
evaluation received telephone interviews and a copy of the most recent 
echocardiographic examination was collected. Follow-up was closed on June 
30st, 2012. 
 
18.2 Statistical analysis 
Continuous data are expressed by mean and standard deviation or median and 
range as appropriate. Categorical data are summarized by reporting the 
percentages. Cumulative survival was estimated using the Kaplan-Meier method 
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and we used the Log–Rank test for comparison between groups. Categorical 
values were compared by the chi-square or Fisher exact test, and continuous 
variables were compared by the t-test.  A stepwise logistic regression analysis 
was used to determine the independent predictive factors of VARC mortality. 
Variables for the multivariate analysis were selected because of recognized 
clinical importance or because they were significantly different at the univariate 
analysis. Statistical analyses were performed using SAS release 8.02 by SAS 
Institute Inc., Cary, NC, USA. 
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18.3 Results 
Pre-operative clinical variables of patients are listed in table 2.  
Table 2. Preoperative cl inical characteristics of Trans-apical TAVI patients enrolled in the I-TA 
registry. This table also shows results of the univariate analysis for thirty-day VARC mortality. 
Variables with the asterisk were included in the multivariate analysis.BMI: body mass index; ES: 
Euroscore; STS: Society of Thoracic Surgeons; AVAi: aortic valve area index; LVEF: left ventricle 
ejection fraction; PAPs: systolic pulmonary artery pressure; NYHA: New York Heart Association; PVD: 
peripheral vascular disease; COPD: chronic obstructive pulmonary disease; CABG: coronary artery 
bypass grafting; AMI: acute myocardial infarction; AF: atrial f ibri l lation; MR: mitral regurgitation; PCI: 
percutaneous coronary intervention; BAV: balloon aortic valvuloplasty. (*):  variables included in the 
multivariate analysis.a: Chronic kidney fai lure defined as creatinine >2 md/dL and/or dialysis. 
Variable  
ALL (N=774) 
n (%) 
ALIVE 
(N=697) 
n (%) 
30-day VARC mortality 
(N=77) 
n (%) 
p Value 
Age (years) * 81.0±6.7 81.0±6.7 82.6±7.9 0.84 
BMI (m2) 25.6±4.9 25.7±5.0 24.5±3.8 0.01 
Creatinine (mg/dl) 1.3±0.9 1.2±0.6 2.0±2.1 0.002 
Glomerular filtration rate (ml/min) 47.4±24.9 48.6±25.3 35.2±17.8 <0.0001 
Hemoglobin (g/dL) 11.9±1.7 12.0±1.7 11.4±1.6 0.007 
Logistic ES I (%) 25.6±16.3 24.7±15.7 33.3±19.4 0.0003 
ES II (%) 9.4±11.0 8.7±9.8 16.5±20.8 0.003 
STS predicted mortality score (%) 10.3±8.4 8.7±10.3 15.2±13.0 0.07 
Peak aortic gradient (mmHg) 80.1±22.9 80.4±22.6 77.8±25.3 0.36 
Mean aortic greadient (mmHg) 49.8±15.4 50.1±15.3 49.2±15.9 0.62 
AVAi  (cm2/mq) 0.48±0.13 0.55±0.19 0.49±0.18 0.013 
LVEF (%) * 52.9±12.8 53.3±12.4 50.3±13.4 0.048 
PAPs (mmHg) 42.8±13.0 42.6±13.0 44.1±13.2 0.43 
Female * 446 (57.6) 405 (58.1) 41 (53.2) 0.41 
Obesity (BMI≥30) * 103 (13.3) 96 (13.8) 7 (9.1) 0.29 
Arterial hypertension * 671 (86.7) 601 (86.2) 70 (90.9) 0.25 
Diabetis Mellitus * 205 (26.5) 188 (27.0) 17 (22.1) 0.36 
NYHA ≥ III 621 (80.2) 574 (82.4) 75 (97.4) 0.0007 
PVD * 384 (49.6) 334 (47.9) 50 (65.0) 0.005 
COPD (ES) 247 (31.9) 224 (32.1) 23(30.0) 0.68 
Neurologic dysfunction * 66 (8.5) 54 (7.8) 12 (15.6) 0.02 
Critical preoperative state * 31 (4.0) 17 (2.4) 14 (18.2) <0.0001 
Previous cardiac surgery  * 
     Previous CABG 
167 (21.6) 
87 (11.2) 
153 (22.0) 
82 (11.7) 
15 (19.5) 
6 (7.8) 
0.62 
0.30 
AMI * 23 (3.0) 17 (2.4) 6 (7.8) 0.02 
Logistic ES I< 10% 116 (15.0) 109 (15.6) 7 (9.1) 0.12 
Logistic ES I≥ 20% 417 (53.9) 363 (52.1) 54 (70.1) 0.003 
Chronic kidney failurea * 80 (10.3) 64 (9.2) 16 (20.8) 0.002 
Dyalisis 28 (3.6) 21 (3.0) 7(9.1) 0.008 
AF 169 (21.8) 151 (21.7) 18 (23.4) 0.73 
Severe MR * 39 (5.0) 30 (4.3) 9 (11.7) 0.02 
Previous PCI 139 (18) 126 (18.0) 13 (16.9) 0.80 
Pocelain aorta 122 (15.8) 108 (15.5) 14 (18.2) 0.54 
Previous aortic BAV 70 (9.0) 64 (9.2) 6 (7.8) 0.68 
Volume center (<28 cases) * 197 (25.5) 173 (24.8) 24 (31.2) 0.22 
Learning curve 
 (first 50% of each center) * 
368 (47.5) 323 (46.3) 45 (58.4) 0.043 
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Mean age was 81.0±6.7 years, mean logistic EUROscore I, EUROscore II and 
STS score was 25.6±16,3%, 9,4±11,0% and 10.6±8.5%, respectively. New York 
Heart Association (NYHA) functional class III or IV was assigned to 621 (80.2 %) 
patients. Almost 50% of patients were suffering from severe peripheral vascular 
disease. Patients who already underwent a cardiac surgery operation were 167 
(21.6%), while 139 (18,0%) patients underwent percutaneous coronary 
angioplasty before TAVI. Sapien/Sapien XT valve size 23, 26 and 29 mm was 
used in 279 (36.1%), 426 (55.0%) and 69 (8.9%) patients, respectively. Device 
success was 95,9% (742 patients). Device success criteria were not met in 32 
(4,1%) patients for the following reasons: suboptimal performance of the 
prosthetic heart valve in 19 (2.5%) patients; 6 (0.8%) rescue “Valve-in-Valve”; 5 
(0.6%) prosthesis embolization; successful access failure in 2 (0.2%) patients. 
Incidence of permanent pacemaker implantation for complete atrio-ventricular 
block was 5.4% (42 patients). Incidence of disabling stroke was 0.6% (5 
patients), while five other patients experienced minor stroke or transient 
ischemic attack. Incidence of acute myocardial infarction was 1,9% (15 patients), 
six (0.7%) patients required bailout percutaneous angioplasty for coronary ostia 
occlusion. Median stay in the intensive care unit was 2 days (Interquartile range: 
1-3) and median hospital stay was 8 days.  
All-cause mortality at 30 days or during index procedure hospitalization (also in 
rehabilitation facilities) was 9.9% (77 patients). Cardiovascular mortality was 
5.0% (39 patients): intra-procedural mortality occurred in 6 (0.7%) patients, 21 
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_________________________________________________________	  
Fig.  40.  Kaplan-Meier analysis  of overall 
survival of pat ients enrolled in the I-TA 
registry 	  
(2.7%) patients died for heart failure, 7 (0.9%) for major ventricular arrhythmias; 
there were 3 (0.4%) deaths for ischemic stroke and 2 (0.3%) sudden deaths. 
Mortality was classified as non cardiac in 4.9% (38 patients): multi-organ failure 
in 13 (1.7%) patients; sepsis in 12 (1.6%) patients, respiratory failure in 7 (0.9%) 
patients, severe hemorrhage in 3 (0.4%) patients, mesenteric ischemia in 2 
patients (0.3%) and one suicide (0.1%).  
The combined early safety endpoint at 30 days, according to VARC-2 
definitions was met in 168 (21,7%) patients while 606 (78,3%) patients had an 
uneventful 30-day outcome.  
We observed 10 apex-related complications (1,2%); of these 2 required the 
institution of cardio-pulmonary bypass (one with conversion to median 
sternotomy) while the remaining 8 were successfully treated off-pump through 
the mini-thoracotomy. 
 
18.3.1 Follow-up 
Median follow-up was 12 months, 
ranging from 1 to 44 months. One-
year overall Kaplan-Meier survival 
was 81,7±1,5%, two-year and three-
year survival was 76,1±1,9% and 
67,6±3,2%, respectively (Fig. 40).  
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Fig.  41. Kaplan Meier freedom from 
cardiovascular  mortality of patients enrol led in 
the I-TA registry 	  
One-year, two-year and three-year freedom from cardiovascular mortality was 
91,2±1,1%, 87,4±1,6% and 83,1±2,4%, respectively (Fig. 41).  
 
There were neither cases of 
structural valve deterioration nor 
endocarditis of the aortic 
bioprosthesis during follow-up. 
The combined clinical efficacy 
endpoint at one year, according 
to VARC-2 definitions, was met 
in 207 patients (26,7%). 
Furthermore we observed a significant improvement of NYHA functional class 
during follow up: preoperatively 82,4% (574 patients) of patients was in class III-
IV versus 18,6% (130 patients) postoperatively (p<0,001). 
 
18.3.2 Learning curve and procedural volume 
We did not observe significant differences of survival at follow up related to the 
learning curve. In fact, Kaplan-Meier analysis of survival found similar overall 
three-year survival of the first 50% patients (66,9±3,8%) versus the second 50% 
patients of each center (69,3±5%) (p=0,64) (Fig. 42). 
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However, thirty-day VARC mortality was significantly higher in the first 50% 
patients (45 out of 368 patients, 12,2%) than the second 50% (32 out of 406 
patients, 7,9%) (p=0,04). Thirty-day VARC mortality of low-volume centers was 
12,2% (24 out of 197 patients) while in high-volume centers it was 9,1% (53 out 
of 577 patients) and this difference was not significant (p=0,22).  
 
18.3.3 Echocardiographic data 
At discharge, no aortic regurgitation was found in 375 patients (53,8%), mild 
(1+/3+), moderate (2+/3+) and severe (3+/3+) aortic insufficiency were found in 
261 (37,4%), 57 (8,2%) and 4 (0,6%), respectively. Peak and mean trans-aortic 
gradients at discharge were 21,0±10.3 mmHg and 10,2±4,1 mmHg, 
respectively; these values remained stable during follow-up. Figure 43 shows 
________________________________________________________________ 
Fig.  42. Kaplan-Meier analysis of  overal l mortality of  the f irst  
50% and the second 50% patients of each center 	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mean gradient and effective orifice area of Sapien/Sapien XT bioprosthesis at 
discharge and during follow up by size.  
	  
________________________________________________________________________________________________________________________________	  
Fig. 43. Transprosthetic gradients and effective orif ice area measured preoperatively, at 
discharge ad at different follow-up intervals. EOA: Effective orif ice area 
 
18.3.4 Multivariate analysis 
Variables that were used in the multivariate analysis are shown in table 2 with an 
asterisk. 
The multivariate analysis identified as independent predictors of 30-day VARC 
mortality: chronic kidney failure (serum creatinine ≥2 mg/dL or dialysis) (OR: 2,2, 
95% Confidence Interval: 1,1-4,2; p: 0,02), neurologic dysfunction (OR: 2,1; 95% 
CI: 1,0-4,3; p: 0,049), peripheral vascular disease (OR: 2,0; 95% CI: 1,2-3,4; 
p:0,008), critical preoperative state (OR: 8,8; 95% CI: 4,0-19,6; p<0,0001), 
learning curve (second 50%) (OR: 0,57; 95 CI: 0,34-0,94; p: 0,02). 
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18.4 Discussion 
This study shows the results of trans-apical TAVI in a “real world” population. 
Our main findings are that trans-apical TAVI can be performed with an 
acceptable mortality rate, safety at 30-day, efficacy at one year as well as three-
year survival and freedom from cardiovascular mortality, in particular if we 
consider the high surgical risk of these patients. All cause mortality was 9,9%, 
this value is similar to that reported by other registries (60, 70, 100). The 30-day 
combined safety endpoint is a composite of patient-oriented endpoints (death, 
stroke, bleeding, kidney injury, myocardial infarction, vascular complications) 
together with a repeat procedure in the first 30 days to treat valve dysfunction 
(balloon valvuloplasty, valve-in-valve). Safety reflects the impact of TAVI on early 
hospital outcomes. In our study, 19,1% of patients met the safety endpoint, of 
these 9,5% were deaths and the remaining 9,6% were complications. This value 
is consistent to that reported by other investigators (101). On the other hand, 
efficacy at one year incorporates major clinical (death and failure of current 
therapy) and valve performance factors (prosthetic valve dysfunction like 
stenosis or regurgitation), thus reflecting the impact of TAVI on delayed 
outcomes (one year or longer period). In our study, the efficacy endpoint was 
met in 20% of patients. These values should be considered with caution since 
these are relatively new criteria, specifically developed for TAVI, and there are 
no studies that use these definitions to evaluate the performance of 
conventional aortic valve replacement (102). A study focused on this issue 
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would be important in order to compare the two procedures and validate these 
composite endpoints. Another important aspect is that out of the 19% of 
patients that met the safety endpoint, in 9,6% a severe complication occurred. 
The complications that are included in the composite safety endpoint are 
usually life threatening and the fact that patients were able to survive such 
events highlights the importance of a multidisciplinary team approach to TAVI. 
In fact, a multidisciplinary team is able to carefully select patients, predict 
potential adverse events, identify and treat complications in a timely and 
effective manner (50). TAVI is a complex procedure that requires a specific 
training and consequently the learning curve may affect outcomes. We 
observed that patients who received trans-apical TAVI during the first half 
experience of each center had a significantly higher 30-day VARC mortality 
when compared to patients operated on during the following period. 
Nevertheless, survival at follow up was similar, reflecting once again the 
importance of comorbidities. The learning curve is therefore crucial for patient 
selection and procedure performance (valve sizing, access, positioning, post-
dilatation) and at the multivariate analysis it was identified as an independent 
predictor of 30-day mortality. On the other hand, procedural volume does not 
seem to have a significant impact on outcomes since 30-day mortality was 
similar between “low-volume” and “high-volume centers”. Medium term 
survival, up to three years, was 67,6% but freedom from cardiovascular mortality 
was 83,1%. This data confirm that the impact of patient comorbidities play a 
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major role in determining survival at follow up (103) and show that probably, the 
extension of indications towards a less compromised population, could improve 
overall survival. Another aspect that is in favor of the indications to TAVI for 
younger patients is that we did not report any case of structural valve 
deterioration in the entire experience. Furthermore, we observed that the 
hemodynamic performance of Sapien bioprosthesis is good, with low gradients 
and significant valve area improvement, and that it remains stable during follow 
up. However, there is still an issue that causes caution and perplexity with 
regard to extension of indications to TAVI to younger or less compromised 
patients: postoperative aortic regurgitation. In this registry, 45% of patients had 
a mild or moderate aortic regurgitation at hospital discharge. This should be 
taken into careful consideration since it has been demonstrated that even mild 
aortic insufficiency significantly reduces survival over time (69).  
This study has several limitations: this is a trans-apical only population that does 
not consider comparable trans-femoral TAVI, trans-aortic TAVI nor conventional 
surgery. There is a not homogeneous distribution of patients among the 
different centers. However this is a common problem related with multicenter 
registries and results reflect the “real world” nature of the study. We did not 
have a central core-lab for echocardiographic examinations and VARC adverse 
events were assigned by the referring center and not by an ad-hoc committee. 
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In conclusion, trans-apical TAVI provides good early and medium term (up to 
three years) clinical and hemodynamic results. Thus, it can be considered as a 
good therapeutic option in high-risk or inoperable patients suffering from 
severe symptomatic aortic valve stenosis. In particular, the hemodynamic 
performance of the Sapien valve is good and it’s stable over time. Postoperative 
aortic insufficiency represents still a major issue and it should be solved with 
new generation devices in order to extend indications to TAVI. Chronic kidney 
failure, neurological dysfunction, peripheral vascular disease, critical 
preoperative state and learning curve were identified as independent predictors 
of VARC thirty-day mortality 
  
	   87	  
Appendix 1: Number of patients enrolled yearly in the I-TA registry by study site 
 Institution 2008 (April-December) 2009 2010 2011 2012 (Jan-Jun) Total 
1 Centro Cardiologico 
Monzino, Milan 
14 49 19 12 1 95 
2 Clinica Montevergine, 
Mercogliano 
32 40 12 5 - 89 
3 University of Padova - 23 26 29 3 81 
4 San Camillo Hospital, 
Rome 
- 15 32 25 5 77 
5 San Bortolo Hospital, 
Vicenza 
3 33 7 9 3 55 
6 University of Bologna 2 12 12 11 1 38 
7 Humanitas Gavazzeni 
Hospital, Bergamo 
6 10 13 7 2 38 
8 University of Pavia - 8 12 14 3 37 
9 University of Turin - 19 5 11 1 36 
10 Clinica S. Anna, 
Catanzaro 
- - 16 14 1 31 
11 G. Pasquinucci Heart 
Hospital, Massa 
2 6 17 2 - 27 
12 Ospedale Mauriziano 
Umberto I, Turin 
- 5 13 8 - 26 
13 S. Raffaele Hospital, 
Milan 
6 9 6 4 - 25 
14 Hesperia Hospital, 
Modena 
- - 7 15 2 24 
15 Humanitas Gavazzeni 
Hospital, Rozzano 
- 2 2 14 2 20 
16 Ospedale dell’Angelo, 
Venice-Mestre 
- 12 5 - - 17 
17 University of Parma - 6 2 7 - 15 
18 S. Maria della 
Misericordia Hospital, 
Udine 
- 8 6 - - 14 
19 S. Croce e Carle 
Hospital, Cuneo 
- - - 14 - 14 
20 Ospedali Riuniti, Trieste - 4 4 - - 8 
21 University of Verona - - 5 2 - 7 
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19. CONVENTIONAL SURGERY, SUTURELESS VALVES AND TRANS-
APICAL AORTIC VALVE REPLACEMENT: WHAT IS THE BEST 
OPTION IN PATIENTS WITH AORTIC VALVE STENOSIS? A 
MULTICENTER, PROPENSITY-MATCHED ANALYSIS. 
 
Aim of this multicenter, propensity-matched study, was to compare hospital 
clinical and hemodynamic outcomes of SAVR, TA-TAVI and SU-AVR. 
 
19.1 Patients and Methods 
This study was approved by ethic committees and patient informed consent for 
data collection and treatment was always collected. 
 
19.1.1 Trans-apical Aortic Valve Replacement 
We reviewed data from 566 patients enrolled in the Italian Registry of Trans-
Apical Aortic Valve Implantation (I-TA) from April 2008 through May 2011. Main 
indication for TA-TAVI was severe symptomatic aortic valve stenosis (Aortic 
valve area <0,8 cm2, mean trans-aortic gradient >40 mmHg) associated to one 
or more of the following: a) porcelain aorta, b) high surgical risk (Logistic 
Euroscore I >20%, Society of Thoracic Surgeons mortality score >10%), c) other 
serious comorbidities as: severe pulmonary disease, previous total chest 
irradiation, hostile chest, severe liver disease. TA-TAVI procedures were 
performed usually under general anesthesia and the only implanted devices 
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were the Sapien and, since mid-2010 the Sapien XT pericardial balloon 
expandable bioprosthesis (Edwards Lifesciences, Irvine, CA, USA). Absolute 
contraindications for TA-TAVI were: a) left ventricular aneurysm with or without 
thrombotic stratification and b) extremely poor left ventricular ejection fraction 
(<15%).  
 
19.1.2 Sutureless Aortic Valve Replacement 
We prospectively collected and analyzed data of 38 patients who underwent 
isolated SU-AVR with the Perceval S bioprosthesis (Sorin Biomedica Cardio, 
Saluggia, Italy) at 3 Italian centers from March to September 2011. Sutureless 
valve data were collected using the same data set of the I-TA to obtain 
homogeneous, comparable, and, most important, reliable data. All SU-AVR 
procedures were performed under moderately hypothermic (32° C) 
cardiopulmonary bypass with aortic cross-clamping and cardioplegic arrest of 
the heart. A transverse aortotomy was performed around 3 to 3.5 cm above the 
aortic annulus, the native valve was removed, and annular decalcification was 
performed. Annular decalcification is not as extensive as for conventional 
surgery, but it is aimed at removing bulky calcifications to obtain a 
homogeneous, round-shaped annulus for sutureless valve implantation. After 
decalcification, the aortic annulus was sized and the correct prosthesis was 
selected. Prosthesis size “small” was selected, with an annulus diameter 
between 19 mm and 21 mm. Size “medium” was selected, with an annulus 
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diameter between 21 mm and 23 mm. During the study period, size “large” 
was still not available. Three 4-0 prolene guiding sutures are passed through the 
aortic annulus at the nadir of each sinus. The delivery system was guided in its 
correct position using these sutures and the valve was deployed. After 
deployment, the delivery system and sutures were removed, and a balloon was 
inserted in the valve and expanded for 30 seconds at a pressure of 3 atm. 
Indications for SU-AVR were as follows: severe symptomatic aortic valve stenosis 
(Aortic valve area <0,8 cm2, mean trans-aortic gradient >40 mmHg)and a high 
surgical risk profile for advanced age (>75 years), comorbidities, and patient 
frailty. Exclusion criteria for the use of a Perceval S valve were: a) previous 
implantation of a valve prosthesis or annuloplasty ring not being replaced by 
the sutureless bioprosthesis, b) double or multiple valve surgery, c) aneurysmal 
dilatation (≥45 mm) or dissection of the ascending aorta, d) active endocarditis, 
e) bicuspid aortic valve and f) recent (<90 days) myocardial infarction. SU-AVR 
was performed with full sternotomy, mini sternotomy or mini thoracotomy, 
according to the type of intervention, the associated procedures, and, 
ultimately, the surgeon’s preferences. In particular, SU-AVR procedures were 
performed through full sternotomy, mini sternotomy and mini right thoracotomy 
in 23 (60,5%), 4 (10,5%) and 11 (29%) patients, respectively. Mean aortic cross-
clamp and cardiopulmonary bypass time were 44±17 and 69±44 minutes, 
respectively.  
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Since there are no guidelines, position statements nor recommendations about 
SU-AVR, the choice between TAVI and SU-AVR, especially in high-risk elderly 
patients, was made by each single surgeon based on patient’s preoperative 
characteristics and clinical observation.  
 
19.1.3 Surgical Aortic Valve Replacement 
We retrospectively collected data from 349 consecutive patients who 
underwent isolated SAVR from January 2009 through December 2011 at the 
University of Padova. We collected data of SAVR patients specifically for this 
study using exactly the same dataset and definitions of SU-AVR and TA-TAVI 
patients. Data were obtained directly from an “ad-hoc” review of official 
hospital medical charts and not from already existing databases. All SAVR 
procedures were performed through full sternotomy, with moderately 
hypothermic cardiopulmonary bypass. Cold-blood cardioplegia was usually 
administered both in antegrade and retrograde fashion. Prostheses were 
implanted with 2-0 braided pledgeted horizontal mattress sutures (pledgets on 
the ventricular side). Bioprostheses and mechanical prostheses were used in 
332 (95,1%) and in 17 (4,9%) patients, respectively. Mean aortic cross-clamp 
and cardiopulmonary bypass time were 93±27 and 124±33 minutes, 
respectively. 
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Patients of all groups underwent clinical and echocardiographic assessment at 
the study site before the procedure and at hospital discharge. 
Echocardiographic measurements were done according to current 
recommendations (9). Prosthetic aortic regurgitation was classified as none or 
trace, mild (1+/3+), moderate (2+/3+), or severe (3+/3+) according to recent 
recommendations (10).  
 
19.1.4 Risk factors and endpoints 
Preoperative risk factors were defined according to the EuroSCORE I 
classification (99), and postoperative outcomes and endpoints were defined 
according to the Valve Academic Research Consortium definitions (95). The 
recently updated VARC 2 definitions (96) were still not available at the time of 
data analysis. For analysis, patients were classified as receiving TA-TAVI or 
“open-heart surgery” (OHS; SU-AVR or SAVR). The database records 10 
explanatory variables: age, sex, body surface area, Logistic Euroscore I, New 
York Heart Association (NYHA) functional class, left ventricular ejection fraction, 
concomitant mitral valve disease, chronic obstructive pulmonary disease, 
peripheral vascular disease and aortic valve area. The dependent variable is a 
categorical variable comparing results of TAVI technique with OHS technique. 
Within OHS we further analyzed results of TA-TAVI vs. SU-AVR and TA-TAVI vs. 
SAVR. Our primary study end-points, defined before analysis, were: all cause 
30-day mortality, disabling stroke, permanent pace-maker implantation, renal 
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replacement therapy, peri-procedural acute myocardial infarction (within 72 
hours after the index procedure), aortic regurgitation at discharge (≥1+/3+) and 
trans-aortic gradient at discharge.  
 
19.2 Statistical analysis 
Analyses were performed using Stata vers.12.1 (StataCorp, Lakeway Drive 
College Station, TX, USA). Preoperative demographic, risk related variables and 
post-operative (30-day) mortality and morbidity outcomes were investigated. 
Categorical variables were expressed as frequencies and compared using the 
Fisher exact and chi-squared test. Continuous variables were expressed as 
mean ± standard deviation and compared using the unpaired t-test. 
Standardized differences were used to assess the degree of baseline variable 
balance by a well-validated technique (104). We estimated the propensity score 
of the treatment category on our 10 explanatory variables using a logit model 
and a default p-value of 0.01. The balancing property was satisfied stratifying 
953 of the original patients in 17 blocks (105). Subsequently a 1:1 match on the 
propensity score, without replacement, was performed using the psmatch2 
procedure (106) with a conservative caliper width of 20% of the standard 
deviation of the log of propensity score (107). Two hundred and eighty six 
patients were successfully matched (143 TA-TAVI and 143 OHS). The psmatch2 
common support option also retained 347 unmatched TAVI. In these patients 
the matching weight was missing, therefore we calculated a weight proportional 
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to the inverse of their inclusion probability within their original stratification 
block. Statistical significance of results was robust to several different weight 
specifications. Comparisons between groups were performed considering the 
matched nature of the propensity score-matched sample. In particular, paired t-
test or Wilcoxon signed rank test were used for continuous variables and 
McNemar test was used for binary (dichotomous) variables. A multivariable 
logistic analysis of the odds ratio of mortality and morbidity was finally 
performed on the 633 patients in common support region adjusting for SU-AVR 
and SAVR technique, preoperative covariates and propensity score. To this 
purpose a weighted logistic model, saturated with event related variables and 
with propensity score inclusion, was used. 
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19.3 Results 
 
Two hundred and eighty six patients were successfully matched: 143 underwent 
TA-TAVI and 143 underwent OHS. Six hundred and thirty three patients were 
included in the common support region of the propensity analysis. Preoperative 
clinical characteristics of patients of the OHS and TA-TAVI cohorts are listed in 
tables 3, 4 and 5. These tables show the unmatched cohorts, the cohorts after 
matching in the common support region and the cohorts after caliper matching. 
In the unmatched cohort (table 3) TA-TAVI patients were older (80,6±6,8 vs. 
72,7±10,1 years; p<0,001) and with a significantly higher logistic Euroscore 
(25,5±15% vs. 14,2±11,2%; p<0,001). Furthermore, TA-TAVI patients had a 
worse New York Heart Association (NYHA) functional class and were more likely 
to suffer from peripheral vascular disease (PVD) (51,2% vs. 36,7%; p<0,001) and 
from chronic obstructive pulmonary disease (COPD) (35,7% vs. 20,9%; 
p<0,001). After matching the two cohorts were similar in terms of body surface 
area, logistic Euroscore, left ventricular ejection fraction, PVD and COPD. After 
matching age was still significantly different among groups, however age is an 
important component of logistic Euroscore, therefore we are confident that 
multivariate logistic regression may adjust for this residual imbalance in the 
observed baseline covariates. Table 6 shows study end-points in the 633 
patients matched in the common support region. Thirty-day overall mortality 
was significantly lower in SAVR than in TA-TAVI (8,6% vs. 0,9%, p=0,002) while 
	   96	  
there were no differences between SU-AVR and TA-TAVI regarding mortality. 
Causes of death in TA-TAVI patients were: multi-organ failure in 15 patients 
(35,7%), sepsis in 10 patients (23,8%), arrhythmias in 6 patients (14,3%), renal 
insufficiency in 2 patients (4,8%), severe hemorrhage in 6 patients (14,3%) and 
mesenteric ischemia in 3 patients (7,1%). One patient died in the SAVR matched 
group for multi-organ failure. No deaths were observed in the SU-AVR matched 
cohort. TA-TAVI had significantly lower trans-aortic gradients when compared 
to SAVR (10,3±4,4 mmHg vs. 16,5±5,8 mmHg, p<0,001) but it was found to 
have a higher incidence of at least mild (≥1+/3+) aortic regurgitation (34,1% vs. 
1,8%; p<0,001). Furthermore, SAVR showed a lower incidence of postoperative 
pacemaker implantation (0,9% vs. 6,1%; p=0.018) and need for renal 
replacement therapy (0% vs. 7,6%; p=0,001). The other endpoints did not 
appear to be different neither between TA-TAVI and SAVR nor between TA-
TAVI and SU-AVR. The analysis of end-points in the 286 caliper 1:1 matched 
patients is shown in table 7. There was still a difference of mortality between 
TA-TAVI and SAVR although the statistical significance was less pronounced 
than the analysis of the common support region (7% vs 1,8%; p=0,026). Also in 
the 1:1 matched cohort, TA-TAVI demonstrated significantly lower gradients 
than SAVR (10,7±4,4 mmHg vs. 16,5±5,8 mmHg, p<0,001) and higher 
incidence of aortic regurgitation (28,7% vs. 1,8%; p<0,001). The multivariate 
analysis showed that SU-AVR had a protective effect, although not statistically 
significant, against aortic regurgitation, pacemaker implantation and renal 
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replacement therapy with respect to TA-TAVI. On the other hand, when 
compared to TA-TAVI, SAVR demonstrated significant protection against aortic 
regurgitation (OR=0,04, p<0,001) and a trend towards protection against death, 
pacemaker implantation and myocardial infarction. The effect of SAVR and SU-
AVR on the pre-defined endpoints, with respect to TA-TAVI, is shown in table 8.  
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Table 3. Characterist ics of patients’ cohorts before matching. OHS: Open-heart 
surgery (Sutureless and surgical aortic valve replacement); TA-TAVI: Trans-apical 
aortic valve replacement; BSA: Body surface area; LVEF: Left ventricular ejection 
fraction; AVAi: Aortic valve area index; NYHA: New York Hear Association; PVD: 
Peripheral vascular disease; COPD: Chronic obstructive pulmonary disease: MR: 
Mitral regurgitation. 
	  
 
 
  
Variable OHS (n=387) TA-TAVI (n=566 ) p-value 
Age (years) 72,7±10,1 80,6±6,8 <0,001 
BSA (m2) 1,8±0,2 1,7±0,2 <0,001 
Logistic Euroscore (%) 14,2±11,2 25,5±15 <0,001 
LVEF (%) 59,1±10,6 52,7±13,6 <0,001 
AVAi (cm2/m2) 0,51±0,1 0,55±0,2 0,001 
Male Sex (%) 48,3 40,8 0,02 
NYHA ≥3 (%) 33,1 83,4 <0,001 
PVD (%) 36,7 51,2 <0,001 
COPD (%) 20,9 35,7 <0,001 
MR (%) 9,6 9,2 0,07 
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Table 4. Characteristics of patients’ cohorts after matching in the 
common support region. OHS: Open-heart surgery (Sutureless and 
surgical aortic valve replacement); TA-TAVI: Trans-apical aortic 
valve replacement; BSA: Body surface area; LVEF: Left ventricular 
ejection fraction; AVAi: Aortic valve area index; NYHA: New York 
Hear Association; PVD: Peripheral vascular disease; COPD: Chronic 
obstructive pulmonary disease: MR: Mitral regurgitation. 
 
 
 
 
 
 
 
 
  
Variable OHS (n=143) TA-TAVI (n=490) p-value 
Age (years) 73,5±12,6 80,4±7 <0,001 
BSA (m2) 1,8±0,3 1,7±0,2 0,001 
Logistic Euroscore (%) 18,3±14,6 24,5±14,1 <0,001 
LVEF (%) 58,1±10,9 53,4±13,6 <0,001 
AVAi (cm2/m2) 0,55±0,2 0,54±0,2 0,93 
Male Sex (%) 49,7 40,8 0,07 
NYHA (%) 54,5 81,2 <0,001 
PVD (%) 37,1 48,8 0,17 
COPD (%) 25,9 33,9 0,08 
MR (%) 24,5 68,2 <0,001 
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Table 5. Characteristics of patients’ cohorts after caliper 1:1 
matching. OHS: Open-heart surgery (Sutureless and surgical aortic 
valve replacement); TA-TAVI: Trans-apical aortic valve replacement; 
BSA: Body surface area; LVEF: Left ventricular ejection fraction; 
AVAi: Aortic valve area index; NYHA: New York Hear Association; 
PVD: Peripheral vascular disease; COPD: Chronic obstructive 
pulmonary disease: MR: Mitral regurgitation. 
 
 
 
  
Variable OHS (n=143) TA-TAVI (n=143) p-value 
Age (years) 73,5±12,6 77,6±9 0,003 
BSA (m2) 1,8±0,3 1,7±0,2 0,12 
Logistic Euroscore (%) 18,3±15,6 20,2±12,5 0,22 
LVEF (%) 58,1±10,9 56,1±13 0,15 
AVAi (cm2/m2) 0,55±0,2 0,55±0,2 0,93 
Male Sex (%) 49,7 37,1 0,03 
NYHA (%) 54,5 65 0,08 
PVD (%) 37,1 42,7 0,43 
COPD (%) 25,9 32,2 0,25 
MR (%) 24,5 32,9 0,06 
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Table 6. Postoperative outcomes after TA-TAVI, SU-AVR and SAVR. 
Analysis made on the 633 patients of the common support region. 
TA-TAVI: Trans-catheter aortic valve replacement; SU-AVR: 
Sutureless aortic valve replacement; SAVR: Surgical aortic valve 
replacement; PPM: Permanent pacemaker Replacement; RRT: Renal 
replacement therapy, AMI: Acute myocardial infarction, AR: Aortic 
regurgitation. Two tail Fisher test  &  ** unpaired t. test 
	  	  	  
 
  
Outcome  TA-TAVI 
(n=490) 
SU-AVR 
(n=31) 
SAVR 
(n=112) 
p-value  
TA-TAVI  
vs. SU-
AVR 
p-value  
TA-TAVI  
vs. SAVR 
Death, n (%) 42 (8,6) 0 1 (0,9) 0.16     0.002      
Stroke, n (%) 12 (2,5) 0 0 1 0,14 
PPM, n (%) 30 (6,1) 1 (3,2) 1 (0,9) 1 0.018 
RRT, n (%) 37 (7,6) 1 (3,2) 0 0.72 0.001 
AMI, n (%) 9 (1,9) 0 1 (0,9) 1 0.70 
Postoperative AR 
(≥1+/3+) 
167 (34,1) 6 (19,4) 2 (1,8) 0.12 <0.001 
Mean Gradient (mmHg)     10,3±4,4 
 
11,1±3,4 16,5±5,8 
 
0.36 ** <0.001 ** 
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Table 7. Postoperative outcomes after TA-TAVI, SU-AVR and SAVR. 
Analysis made on the 286 patients with caliper matching 1:1. TA-
TAVI: Trans-catheter aortic valve replacement; SU-AVR: Sutureless 
aortic valve replacement; SAVR: Surgical aortic valve replacement; 
PPM: Permanent pacemaker Replacement; RRT: Renal replacement 
therapy, AMI: Acute myocardial infarction, AR: Aortic regurgitation. 
Two tail Fisher test  &  ** unpaired t. test  
 
  
Outcome  TA-TAVI 
(n=143) 
SU-AVR 
(n=31) 
SAVR 
(n=112) 
p-value  
TA-TAVI 
vs. SU-
AVR 
p.value  
TA-TAVI vs. 
SAVR 
Death, n (%) 10 (7) 0 1 (1,8) 0,21 0,026 
Stroke, n (%) 4 (2,8) 0 0 1 0,13 
PPM, n (%) 7 (4,9) 1 (3,2) 1 (0,9) 1 0,082 
RRT, n (%) 7 (4,9) 1 (3,2) 0 1 0,019 
AMI, n (%) 5 (3,5) 0 1 (0,9) 0,59 0,23 
Postoperative 
AR (≥1+/3+) 
41 (28,7) 6 (19,4) 2 (1,8) 0, 37 <0,001 
Mean Gradient 
(mmHg) 
10,7±4,4            11,1±3,3 16,5±5,8               0,69 ** <0,001 ** 
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Table 8. Postoperative clinical outcomes after matching and 
multivariate analysis.SU-AVR: Sutureless aortic valve replacement; 
TA-TAVI: Trans-apical aortic valve replacement; SAVR: Surgical 
aortic valve replacement; OR: Odds ratio; AR: Aortic Regurgitation; 
PM: Pace-maker; RRT: Renal replacement therapy; AMI: Acute 
myocardial infarction. *multivariable adusted, logistic Z test   
 
 
 
 
 
Outcome SU-AVR vs. TA-
TAVI 
p-value 
* 
SAVR vs. TA-
TAVI 
p-value 
* 
Death (OR) 1,00 - 0,23 0,17 
Postoperative AR (≥1+/3+) (OR) 0,55 0,23 0,04 <0,001 
Stroke (OR) 1,00 - 1,00 - 
PM implantation (OR) 0,51 0,53 0,97 0,14 
RRT (OR) 0,61 0,68 1,00 - 
AMI (OR) 1,00 - 0,38 0,47 
Mean gradient at discharge 
(OR) 
1,02 0,56 1,19 <0,001 
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19.4 Discussion 
 
The complete portfolio of aortic valve substitutes includes SAVR, SU-AVR and 
TAVI. This is the first study that evaluates and compares, with a propensity 
matched analysis, the results of all these techniques in patients suffering from 
severe symptomatic aortic valve stenosis. Although this should be considered a 
preliminary study, it gives some important insights into this contemporary and 
controversial issue. The main findings of this study were that SU-AVR and SAVR 
might potentially have some advantages over TAVI, in selected patients. This 
may be due to the patient selection process that occurred in our analysis. The 
attempt to match these three cohorts has selected the “worse” open-heart 
patients and the “best” TAVI patients. This was clearly shown in tables 3, 4 and 
5, where the matched TA-TAVI cohort had less comorbidities and lower logistic 
Euroscore values than the unmatched cohort and where matched SAVR patients 
had more comorbidities and higher logistic Euroscore values than the 
unmatched cohort. Thus, as stated in our previous article, these patients belong 
to a “grey-zone” where there is an overlap of indications for the different 
procedures (108). However, even if the three groups after matching were similar 
(especially after 1:1 caliper matching), other factors that might have a significant 
impact on patient outcomes, such as frailty, were not taken into account. It is 
likely that these patients, who belong to they “grey-zone” of surgical risk, were 
assigned to one treatment or to the other one due to one of these unaccounted 
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conditions. The empiric proportions in table 4 and 5 show that SAVR has a 
significantly lower rate of death than TA-TAVI in matched patients. This seems 
to be in contrast with the results from the PARTNER trial (49) but it could be 
explained by several reasons. The PARTNER trial was a prospective randomized 
trial with strict inclusion and exclusion criteria, which was conducted in selected 
centers that considered both trans-apical and trans-femoral TAVI, while our 
study was based on the analysis of data from patients that were operated on in 
the “real world”. We only took into consideration TA-TAVI and not trans-
femoral TAVI. Furthermore, patient characteristics were different from the 
PARTNER trial; in particular the Logistic Euroscore of PARTNER SAVR patients 
was 29% while in our study it was 18% (taking into account also SU-AVR 
patients) and this could explain the different rate of 30-day mortality between 
these two studies (PARTNER: 6,5%, our study: 0,9%). However the power of the 
test in 1:1 match is 46 % and in the multivariate analysis, TA-TAVI was not found 
to be an independent predictor of mortality, thus this result should be 
interpreted with caution. Even if the rate of aortic regurgitation (AR) in SU-AVR 
patients could seem high (19%) one should consider that all leaks were mild 
(1+/3+), that this incidence is similar to other series (31) and that this was a very 
early experience with learning curve-related issues. In the multivariate analysis 
SU-AVR seems to reduce the risk of post-operative AR, permanent pacemaker 
implantation and renal replacement therapy over TA-TAVI. However, the only 
statistically significant difference was found to be the reduction of AR in SAVR 
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patients vs. TA-TAVI patients. Postoperative AR is a highly debated issue, 
especially after the results of the PARTNER trial at 2-years that showed that 
even a mild degree of AR significantly worsen patient survival (69). The reason 
for an AR reduction in SU-AVR are mainly due to the “open-heart” implantation 
of sutureless valves; this enables the surgeon to remove valve leaflets as well as 
annular calcifications and to directly measure the aortic annulus in order to 
choose the most appropriate prosthesis size. Furthermore, the prosthesis is 
implanted under direct vision and, if the final result is not satisfactory, the valve 
can be removed and repositioned either during the same aortic clamping or 
with a second aortic clamping if the leak is discovered only with intraoperative 
trans-esophageal echo (30). The presence and distribution of calcium within the 
aortic annulus has been demonstrated to predict AR after TAVI (91), thus its 
removal may have an impact on reducing postoperative AR. All the above-
mentioned mechanisms explain also the advantage of SAVR over TAVI in the 
reduction of the risk of AR. In fact, postoperative AR is still a major issue that 
should be solved before TAVI indications could be expanded towards younger 
patients and in general towards a lower risk population. Another important issue 
related to TAVI is the rate of postoperative permanent pacemaker implantation. 
Although self-expandable devices were associated with a significantly higher 
incidence of pacemaker implantation than balloon-expandable valves (109), 
there was still a significant advantage of “open-heart” devices over TAVI. In 
fact, the “blind” lateral displacement of aortic annulus calcifications that occurs 
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during TAVI (both during balloon aortic valvuloplasty and during valve 
deployment ) rather than their “surgical” removal that is usually performed in 
SU-AVR and SAVR, might explain the higher incidence of conduction tissue 
injuries. We also found that TA-TAVI patients have significantly lower gradients 
than “open-heart” devices. The hemodynamic behavior of trans-catheter valves 
was therefore better than that of conventional aortic prostheses. However, 
further larger studies with longer follow-up will be able to tell if these 
differences also have a significant clinical impact. With this study we want to 
highlight that surgical aortic valve replacement is still the best choice in patients 
with aortic valve stenosis. However, new therapeutic options such as TAVI and 
sutureless aortic valve prostheses provide good results in selected patients. A 
center that is able to offer to its patients all these therapeutic alternatives may 
select the most appropriate technique tailoring the choice on each single 
patient taking into consideration all crucial characteristics like age, 
comorbidities, frailty and anatomy. A particularly careful evaluation is needed in 
the “grey-zone” patients who can benefit from either one or another technique. 
An experienced “aortic team” will be able to make the most appropriate 
choice. The limitations of this study were mainly related to the retrospective 
nature of the study, to the different procedures made in different centers, to the 
inclusion of TA-TAVI only patients and to the small number of patients in the 
SU-AVR cohort. In conclusion, our data show that there are no main differences 
in outcomes among SAVR, TA-TAVI and SU-AVR. SAVR was associated with a 
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significant reduction of postoperative aortic regurgitation when compared to 
TA-TAVI that, however, showed lower trans-aortic gradients. SU-AVR, when 
compared to TA-TAVI, did not show significant differences even if a trend 
towards less aortic regurgitation was evident. Further larger and possibly 
prospective studies are needed to confirm our preliminary results. 
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possibile.  
Un grazie a mia madre che appoggia e accetta la mia scelta di lontananza, 
nonostante questo significhi per lei vivere senza tutti i suoi affetti più cari. 
Un grazie a mio padre che sento sempre vicino, mi manchi. 
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Una persona importante che mi ha cresciuto, sostenuto ed indirizzato, sia 
professionalmente sia umanamente in questi ultimi quindici anni è il Dott. 
Alessandro Fabbri. Grazie per avermi fatto amare questa professione e per 
essere sempre stato disponibile in qualunque momento, a qualunque ora, in 
qualunque parte del Mondo.  
 
A Gennaio 2010 è iniziata la mia avventura nella Cardiochirurgia di Padova. Un 
grazie sincero al Prof. Gino Gerosa che ha creduto in me e che mi ha accolto 
nella sua equipe. Grazie per avermi messo nelle condizioni ottimali per 
sviluppare il progetto del registro I-TA, oggetto primario di questo Dottorato. 
Grazie per i preziosi consigli e per permettermi di mantenere una costante 
crescita tecnica, culturale e scientifica.  
 
Grazie al Prof. Gaetano Thiene che, nonostante la sua esperienza e la sua 
posizione accademica, mantiene sempre vivo l’interesse e la curiosità per tutti 
gli aspetti della Patologia Cardiovascolare, dal basic science alla ricerca clinica.  
Grazie alla Prof.ssa Cristina Basso che mi ha consigliato e guidato in questi anni 
di Dottorato. 
 
Un grazie a tutti i membri del “TAVI Team” che hanno reso il programma TAVI 
dell’Università di Padova tra i più apprezzati sia a livello nazionale sia a livello 
internazionale. 
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Un grazie agli specializzandi, infermieri, tecnici, segretarie e a tutti coloro che 
hanno collaborato per raccogliere i dati, eseguire le analisi, inviare gli abstract, 
preparare i manoscritti e le diapositive per tutti gli studi che sono stati prodotti 
nel corso di questo Dottorato. 
Infine, un grazie a tutti i colleghi della Cardiochirurgia di Padova che mi hanno 
permesso di vivere l’esperienza negli USA, un indimenticabile periodo sia dal 
punto di vista professionale sia, soprattutto, da quello umano. 
